

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009			
		5089500	JUN 26, 2009			
		5047407	NOV 17, 2009	U248	NCE	DEC 17, 2003
		5905082	MAY 18, 2016		PED	JUN 17, 2004
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		5034394*PED	DEC 26, 2009			
		5047407*PED	MAY 17, 2010			
		5089500*PED	DEC 26, 2009	U248		
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U248		
		6294540	MAY 14, 2018	U65		
		6294540*PED	NOV 14, 2018	U65		
		6180639*PED	JUL 30, 2018	U248		
		6417191	MAR 28, 2016	U248		
4837208	SEP 17, 2005					
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540	MAY 14, 2018	U65		
		6294540*PED	NOV 14, 2018	U65		
		5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540*PED	NOV 14, 2018	U65		
		5089500	JUN 26, 2009	U248		
		5089500*PED	DEC 26, 2009			
021320 001	ABARELIX;PLENAXIS	5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540	MAY 14, 2018	U65		
		6294540*PED	NOV 14, 2018	U65		
		5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
020482 001	ACARBOSE;PRECOSE	5089500*PED	DEC 26, 2009		NCE	NOV 25, 2008
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540*PED	NOV 14, 2018	U65		
		5089500	JUN 26, 2009	U248		
		5089500*PED	DEC 26, 2009			
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540*PED	NOV 14, 2018	U65		
		6294540	MAY 14, 2018	U65		
020482 002	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
		4904769	FEB 27, 2007			
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
		4904769	FEB 27, 2007			
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U296		
		4943565	JUL 24, 2007			
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS/HEADACHE	5004613	JUL 27, 2007		NC	MAR 01, 2004
		4820522	JUL 27, 2007			
		4968509	NOV 06, 2007			
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
		6261546	APR 29, 2019	U506		
		4650807	MAR 26, 2008	U93		
		4963555	OCT 16, 2007		NDF	DEC 30, 2005
		4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
		4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
		4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
020748 001	ADAPALENE;DIFFERIN	6451340	JUL 23, 2018	U470	NCE	SEP 20, 2007
		4808716	APR 25, 2006			
		5663159	SEP 02, 2014	U470		
		4724233	APR 21, 2006	U470		
		4724233	APR 21, 2006			
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	4808716	APR 25, 2006			
		5663159	SEP 02, 2014	U470		
		4724233	APR 21, 2006	U470		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019937 002	ADENOSINE;ADENOCARD	4673563	JUN 16, 2004	U38		
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U116		
		5731296	MAR 24, 2015	U221		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U282		
		5763454	JUN 15, 2015	U282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U282		
		5763454	JUN 15, 2015	U282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020899 001	ALBUMIN HUMAN;OPTISON	5573751	APR 25, 2012			
		5529766	JUN 25, 2013	U505		
		5558094	FEB 28, 2012	U505		
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015			
020950 001	ALBUTEROL SULFATE;DUONEB	6632842	DEC 28, 2021	U532	NP	MAR 21, 2004
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
		5225183	JUL 06, 2010			
		5766573	JUN 16, 2015			
		6352684	NOV 28, 2009			
		5695743	JUL 06, 2010	U491		
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012			
019604 001	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
019604 002	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		I-309	SEP 29, 2003
		4621077	AUG 06, 2007	U114	PED	MAR 29, 2004
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
		6194004*PED	JUN 02, 2013			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207*PED	JUN 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
		5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		6008207	JUN 06, 2015		PED	APR 20, 2004
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 16, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
		6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
020560 005	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		5994329	JUL 17, 2018		PED	APR 20, 2004
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
		4621077	AUG 06, 2007		I-309	SEP 29, 2003
		021575 001	ALENDRONATE SODIUM;FOSAMAX	4621077*PED	FEB 06, 2008	
5462932	MAY 17, 2014				D-61	OCT 20, 2003
5994329	JUL 17, 2018				PED	APR 20, 2004
5994329*PED	JAN 17, 2019					
6015801	JUL 17, 2018					

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021287 001	ALFUZOSIN HYDROCHLORIDE;UROXATRAL	6015801*PED 6225294 6225294*PED 4661491 6149940	JAN 17, 2019 JUL 17, 2018 JAN 17, 2019 MAY 27, 2006 AUG 22, 2017		NCE	JUN 12, 2008
020886 001	ALITRETINOIN; PANRETIN				ODE NCE	FEB 02, 2006 FEB 02, 2004
021001 001	ALMOTRIPTAN MALATE; AXERT	5565447	MAY 07, 2015		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE; AXERT	5565447	MAY 07, 2015		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE; LOTRONEX	5360800 6284770	JAN 13, 2013 OCT 05, 2018	DS DP U405 U405	NCE	FEB 09, 2005
021107 002	ALOSETRON HYDROCHLORIDE; LOTRONEX	5360800 6284770	JAN 13, 2013 OCT 05, 2018	DS DP U405 U405	NCE	FEB 09, 2005
018276 004	ALPRAZOLAM; XANAX	5061494	OCT 29, 2008			
021434 001	ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
021434 002	ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
021434 003	ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
021434 004	ALPRAZOLAM; XANAX XR				NDF	JAN 17, 2006
020379 001	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015			
020379 002	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015			
020379 003	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015			
020379 004	ALPROSTADIL; CAVERJECT	5741523	APR 21, 2015			
021212 001	ALPROSTADIL; CAVERJECT				NP	JUN 11, 2005
021212 002	ALPROSTADIL; CAVERJECT				NP	JUN 11, 2005
020700 001	ALPROSTADIL; MUSE	5242391 4801587	SEP 07, 2010 JAN 31, 2007	U155 U155		
020700 002	ALPROSTADIL; MUSE	5474535 4801587	DEC 12, 2012 JAN 31, 2007	U155 U155		
020700 003	ALPROSTADIL; MUSE	5242391 5474535	SEP 07, 2010 DEC 12, 2012	U155 U155		
020700 004	ALPROSTADIL; MUSE	4801587 5242391	JAN 31, 2007 SEP 07, 2010	U155 U155		
020221 001	AMIFOSTINE; ETHYOL	5474535 5424471 5591731	DEC 12, 2012 JUL 31, 2012 JUL 31, 2012	U155	ODE	JUN 24, 2006
020221 002	AMIFOSTINE; ETHYOL	5994409 5424471 5591731	DEC 08, 2017 JUL 31, 2012 JUL 31, 2012	U305	ODE	JUN 24, 2006
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN	5994409 5079262 5211938	DEC 08, 2017 JUL 28, 2009 MAY 18, 2010	U305 U289 U289	NCE	DEC 03, 2004
020511 001	AMLEXANOX; APHTHASOL	5422093 5954703	JUL 28, 2009 OCT 31, 2017	U289 U289		
020364 002	AMLODIPINE BESYLATE; LOTREL	5362737 4410520 4879303 4572909 6162802 4410520*PED	NOV 08, 2011 AUG 11, 2003 MAR 25, 2007 JUL 31, 2006 DEC 19, 2017 FEB 11, 2004	U243 U367		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020364 003	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003	U367		
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017			
		4410520*PED	FEB 11, 2004			
020364 004	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003	U367		
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017			
		4410520*PED	FEB 11, 2004			
020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003	U367	NS PED	JUN 20, 2005 DEC 20, 2005
		4572909	JUL 31, 2006			
		4879303	MAR 25, 2007			
		6162802	DEC 19, 2017			
		4410520*PED	FEB 11, 2004			
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP PED	JAN 08, 2007 JUL 08, 2007
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
		4879303	MAR 25, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP PED	JAN 08, 2007 JUL 08, 2007
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
		4879303	MAR 25, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP PED	JAN 08, 2007 JUL 08, 2007
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
		4879303	MAR 25, 2007			
020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4 PED	AUG 25, 2003 FEB 25, 2004
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	OCT 21, 2018		NDF	OCT 11, 2004
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6605300	OCT 21, 2018			
		6322819	OCT 21, 2018		NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6605300	OCT 21, 2018			
		6322819	OCT 21, 2018		NDF	OCT 11, 2004
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6605300	OCT 21, 2018			
		6322819	OCT 21, 2018		NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6605300	OCT 21, 2018			
		6322819	OCT 21, 2018		NDF	OCT 11, 2004
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6605300	OCT 21, 2018			
		6322819	OCT 21, 2018		NDF	OCT 11, 2004
011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6605300	OCT 21, 2018			
011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020			
011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020			
011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020			
011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020			
011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020			
011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020			
040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
050724 001	AMPHOTERICIN B;ABELCET				ODE	OCT 18, 2003

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
050740 001	AMPHOTERICIN B; AMBISOME				ODE	AUG 11, 2004
021007 001	AMPRENAVIR; AGENERASE	5723490	MAR 03, 2015	U257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR; AGENERASE	5723490	MAR 03, 2015	U257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U257		
		5585397	DEC 17, 2013			
021039 001	AMPRENAVIR; AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
		5723490	MAR 03, 2015	U257		
		5646180	JUL 08, 2014	U257		
020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				ODE	MAR 14, 2004
020333 002	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				ODE	MAR 14, 2004
020541 001	ANASTROZOLE; ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
					I-363	SEP 05, 2005
019779 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	5212196	MAY 18, 2010	U120		
021549 001	APREPITANT; EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
		5538982	JUL 23, 2013			
		6048859	JUN 29, 2012			
		6096742	JUL 01, 2018			
		6235735	JUN 29, 2012			
021549 002	APREPITANT; EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
		5538982	JUL 23, 2013			
		6048859	JUN 29, 2012			
		6096742	JUL 01, 2018			
		6235735	JUN 29, 2012			
020420 001	ARBUTAMINE HYDROCHLORIDE; GENESA	5108363	APR 28, 2009	U220		
		5234404	AUG 10, 2010	U220		
		5395970	MAR 07, 2012			
020883 001	ARGATROBAN; ARGATROBAN	5214052	MAR 13, 2012		NCE	JUN 30, 2005
		5925760	AUG 04, 2017		I-352	APR 03, 2005
021436 001	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 002	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 003	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 004	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 005	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 006	ARIPIRAZOLE; ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021248 001	ARSENIC TRIOXIDE; TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
020884 001	ASPIRIN; AGGRENOL	6015577	JAN 18, 2017	U302		
021317 001	ASPIRIN; BAYER EXTRA STRENGTH ASPIRIN FOR				NP	OCT 18, 2004
021387 001	ASPIRIN; PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021387 002	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		5180589	JUL 09, 2008			
021387 003	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	5180589*PED	JAN 09, 2009			
		4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
021387 004	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
021387 005	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
021387 006	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
021567 001	ATAZANAVIR SULFATE;REYATAZ	5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021567 002	ATAZANAVIR SULFATE;REYATAZ	5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021567 003	ATAZANAVIR SULFATE;REYATAZ	5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005		
5686104	NOV 11, 2014	U213	PED	APR 18, 2006		
5969156	JUL 08, 2016					
6126971	JAN 19, 2013					
4681893*PED	MAR 24, 2010	U161				
5273995*PED	JUN 28, 2011	U162				
5686104*PED	MAY 11, 2015	U213				
5969156*PED	JAN 08, 2017					
6126971*PED	JUL 19, 2013					
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005		
5686104	NOV 11, 2014	U213	PED	APR 18, 2006		
5969156	JUL 08, 2016					
6126971	JAN 19, 2013					
4681893*PED	MAR 24, 2010	U161				
5273995*PED	JUN 28, 2011	U162				
5686104*PED	MAY 11, 2015	U213				
5969156*PED	JAN 08, 2017					
6126971*PED	JUL 19, 2013					
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005		
5686104	NOV 11, 2014	U213	PED	APR 18, 2006		
5969156	JUL 08, 2016					
6126971	JAN 19, 2013					
4681893*PED	MAR 24, 2010	U161				
5273995*PED	JUN 28, 2011	U162				
5686104*PED	MAY 11, 2015	U213				
5969156*PED	JAN 08, 2017					
6126971*PED	JUL 19, 2013					
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U406	NC	JUL 14, 2003
		5053432	OCT 01, 2008		PED	JAN 14, 2004
		6291488	NOV 25, 2013			
		5053432*PED	APR 01, 2009			
		6166046*PED	MAY 25, 2014			
		6291488*PED	MAY 25, 2014			



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013		NC	JUL 14, 2003
		5053432	OCT 01, 2008		PED	JAN 14, 2004
		6291488	NOV 25, 2013	U406	NPP	DEC 02, 2006
		5053432*PED	APR 01, 2009		PED	JUN 02, 2007
		6166046*PED	MAY 25, 2014			
020259 001	ATOVAQUONE;MEPRON	6291488*PED	MAY 25, 2014			
		4981874	AUG 15, 2009	U69		
		5053432	OCT 01, 2008			
		5053432*PED	APR 01, 2009			
		4981874*PED	FEB 15, 2010	U69		
020500 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U69	ODE	JAN 05, 2006
		5053432	OCT 01, 2008		PED	JUL 05, 2006
		5053432*PED	APR 01, 2009			
		4981874*PED	FEB 15, 2010	U69		
		6649659	JUL 10, 2016	DS DP U69		
6649659*PED	JAN 10, 2017					
019677 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U54		
019678 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U54		
021470 001	AZELAIC ACID;FINACEA	4713394	JAN 17, 2006	U492	NDF	DEC 24, 2005
		6534070	NOV 18, 2018			
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2011	U207		
021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194*PED	MAY 01, 2012			
		5164194	NOV 01, 2010		PED	NOV 22, 2003
021589 001	BACLOFEN;KEMSTRO	5164194*PED	MAY 01, 2011			
		6024981	APR 09, 2018	DP		
021589 002	BACLOFEN;KEMSTRO	6221392	APR 09, 2018	DP		
		6024981	APR 09, 2018	DP		
6221392	APR 09, 2018	DP				
020610 001	BALSALAZIDE DISODIUM;COLAZAL				NCE	JUL 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015		NP	SEP 15, 2003
		5605674	FEB 25, 2014		NPP	MAY 10, 2005
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U356		
		6352684	NOV 28, 2009			
		5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
5766573	NOV 28, 2009	U356				
6352684	NOV 28, 2009					
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	4410520	AUG 11, 2003		NP	SEP 15, 2003
		4410520*PED	FEB 11, 2004		NPP	MAY 10, 2005
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020032 001	BERACTANT; SURVANTA	4397839	JUL 01, 2005			
020576 001	BETAINE, ANHYDROUS; CYSTADANE				ODE	OCT 25, 2003
019716 001	BETAMETHASONE DIPROPIONATE; DIPROLENE	4775529	MAY 21, 2007			
019555 001	BETAMETHASONE DIPROPIONATE; DIPROLENE AF	4489071	DEC 09, 2003			
020010 001	BETAMETHASONE DIPROPIONATE; LOTRISONE				NP	DEC 08, 2003
020934 001	BETAMETHASONE VALERATE; LUXIQ	6126920	MAR 01, 2016	U484		
020619 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC PILO	5635172	JUN 03, 2014	U191		
019845 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC S	4911920	MAR 27, 2007			
021055 001	BEXAROTENE; TARGRETIN	5780676	JUL 14, 2015	U509	NCE	DEC 29, 2004
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
		5962731	OCT 05, 2016	U475		
021056 001	BEXAROTENE; TARGRETIN	5780676	JUL 14, 2015	U510	NCE	DEC 29, 2004
		5962731	OCT 05, 2016		ODE	DEC 29, 2006
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE; CASODEX	4636505	OCT 01, 2008			
021275 001	BIMATOPROST; LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
		6403649	SEP 21, 2012	U446		
020873 001	BIVALIRUDIN; ANGIOMAX	5196404	MAR 23, 2010		NCE	DEC 15, 2005
021602 001	BORTEZOMIB; VELCADE	5780454	OCT 28, 2014		NCE	MAY 13, 2008
		6083903	OCT 28, 2014	U515	ODE	MAY 13, 2010
		6297217	OCT 28, 2014	U515		
		6617317	OCT 28, 2014			
021290 001	BOSENTAN; TRACLEER	5292740	NOV 20, 2015	DS DP	ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN; TRACLEER	5292740	NOV 20, 2015		ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE; ALPHAGAN				NPP	DEC 20, 2004
					PED	JUN 20, 2005
020613 001	BRIMONIDINE TARTRATE; ALPHAGAN	6194415	JUN 28, 2015	U394	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U394	PED	JUN 20, 2005
		6194415*PED	DEC 28, 2015	U394		
		6248741*PED	DEC 28, 2015	U394		
		6465464	JUN 28, 2015	U394		
		6465464*PED	DEC 28, 2015	U394		
021262 001	BRIMONIDINE TARTRATE; ALPHAGAN P	6194415*PED	DEC 28, 2015	U395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U399	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U395	PED	JUN 20, 2005
		6194415	JUN 28, 2015	U395		
		6248741*PED	DEC 28, 2015	U395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
		6465464	JUN 28, 2015	U395		
		6465464*PED	DEC 28, 2015	U395		
		6562873	JUL 10, 2021			
		6562873*PED	JAN 10, 2022			
		6627210	JUL 18, 2021		DP	
		6627210*PED	JAN 18, 2022			
		6641834	JUL 28, 2021		DP	
		6641834*PED	JAN 28, 2022			
		6673337	JUL 26, 2021		DP	
		6673337*PED	JAN 26, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
076260 001	BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE				PC	SEP 16, 2003
020816 001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U224		
		5378703	APR 01, 2012	U224		
		5461081	OCT 24, 2012	U225		
019672 001	BROMPHENIRAMINE MALEATE;EFIDAC 24 PSEUDOEPHEDRINE HCL/BRO	4810502	MAR 14, 2006			
		4662880	MAR 14, 2006			
		4801461	MAR 14, 2006			
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020441 002	BUDESONIDE;PULMICORT	5643602*PED	JAN 01, 2015		PED	APR 02, 2005
		4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		M-22	OCT 26, 2004
		6291445*PED	OCT 29, 2017		PED	APR 26, 2005
020746 002	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		M-22	OCT 26, 2004
		6291445*PED	OCT 29, 2017		PED	APR 26, 2005
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 002	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5427798	AUG 12, 2013		M-10	JUN 11, 2004
		5358970	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020358 004	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970 5427798 5731000 5763493	AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013		M-10	JUN 11, 2004
021515 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341 6143327	OCT 30, 2018 OCT 30, 2018		M-10	JUN 11, 2004
021515 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341 6143327	OCT 30, 2018 OCT 30, 2018		M-10	JUN 11, 2004
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970 5427798 5731000 5763493	AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970 5427798 5731000 5763493	AUG 12, 2013 AUG 12, 2013 AUG 12, 2013 AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12 PED W	JUL 19, 2004 JAN 19, 2005 JUL 19, 2004
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12 PED W	JUL 19, 2004 JAN 19, 2005 JUL 19, 2004
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12 PED W	JUL 19, 2004 JAN 19, 2005 JUL 19, 2004
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12 PED W	JUL 19, 2004 JAN 19, 2005 JUL 19, 2004
021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646 5015646*PED	MAY 14, 2008 NOV 14, 2008			
021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED 5015646	NOV 14, 2008 MAY 14, 2008			
021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646 5015646*PED	MAY 14, 2008 NOV 14, 2008			
021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646 5015646*PED	MAY 14, 2008 NOV 14, 2008			
020954 001	BUSULFAN;BUSULFEX	5430057 5559148 5430057*PED 5559148*PED	SEP 30, 2013 MAY 24, 2015 MAR 30, 2014 NOV 24, 2015	U263 U264 U263 U264	ODE PED	FEB 04, 2006 AUG 04, 2006
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U177	I-333	JUN 06, 2004
021408 001	BUTENAFINE HYDROCHLORIDE;MENTAX-TC				NP	OCT 17, 2005
019881 001	BUTOCONAZOLE NITRATE;GYNAZOLE-1	5266329	NOV 30, 2010	U457		
020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005			
020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U227		
		5759565	MAR 31, 2015			
018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
075766 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075766 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
		6576665	APR 03, 2021			
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U381		
		6576665	APR 03, 2021			
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U349	NC	OCT 15, 2003
		5817340	DEC 01, 2012		PED	APR 15, 2004
		5989588	SEP 30, 2015	U349		
		5989588*PED	MAR 30, 2018	U349		
		5229137*PED	NOV 16, 2012			
		5817340*PED	JUN 01, 2013			
020577 001	CALCIUM CHLORIDE;ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U3	NC	SEP 05, 2003
		5721263	FEB 24, 2015	U3		
		5958961	JUN 06, 2014	U3		
		5196444	JUN 04, 2012	U3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U3		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021093 002	CANDESARTAN CILEXETIL; ATACAND HCT	5705517	APR 18, 2011	U3	NC	SEP 05, 2003
		5721263	FEB 24, 2015	U3		
		5958961	JUN 06, 2014	U3		
		5196444	JUN 04, 2012	U3		
		5534534	JUL 09, 2013			
020896 001	CAPECITABINE; XELODA	5703110	APR 18, 2011	U3	I-323	APR 30, 2004
		5472949	DEC 14, 2013	U271		
020896 002	CAPECITABINE; XELODA	4966891	JAN 13, 2011	U272	I-341	SEP 07, 2004
		5472949	DEC 14, 2013	U271		
020896 002	CAPECITABINE; XELODA	4966891	JAN 13, 2011	U272	I-323	APR 30, 2004
		5472949	DEC 14, 2013	U271		
018343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U92	I-341	SEP 07, 2004
		5238924	AUG 24, 2010	U92		
018343 002	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
018343 003	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
018343 004	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
018343 005	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
018343 006	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
018343 007	CAPTROPIL; CAPOTEN	5238924	AUG 24, 2010	U92		
020712 001	CARBAMAZEPINE; CARBATROL	5326570	JUL 05, 2011	U215		
		5912013	JUN 15, 2016	U277		
020712 002	CARBAMAZEPINE; CARBATROL	5326570	JUL 05, 2011	U215		
		5912013	JUN 15, 2016	U277		
020234 001	CARBAMAZEPINE; TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 002	CARBAMAZEPINE; TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 003	CARBAMAZEPINE; TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
019856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
021485 002	CARBIDOPA; STALEVO 100	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 003	CARBIDOPA; STALEVO 150	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 001	CARBIDOPA; STALEVO 50	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
019880 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
019880 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
019880 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		
020452 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U175		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006		ODE	SEP 23, 2003
		4757128	AUG 01, 2006		I-382	FEB 25, 2006
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013		I-399	JAN 07, 2006
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	6136783	MAR 28, 2017			
		5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013		I-399	JAN 07, 2006
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
021222 001	CEFDITOREN PIVOXIL;SPECTRACEF	6136783	MAR 28, 2017			
		4839350	JUN 13, 2006		NCE	AUG 29, 2006
		4918068	JUN 13, 2006		I-364	AUG 21, 2005
		5958915	OCT 14, 2016			
020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U19	NCE	DEC 31, 2003
		5466823	NOV 30, 2013		I-338	OCT 17, 2004
		5563165	NOV 30, 2013			
		5972986	OCT 14, 2017	U299		
020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U299		
		5760068	JUN 02, 2015	U19	NCE	DEC 31, 2003
		5466823	NOV 30, 2013		I-338	OCT 17, 2004
		5563165	NOV 30, 2013			
		5760068	JUN 02, 2015	U299		
		5972986	OCT 14, 2017	U299		
020998 003	CELECOXIB;CELEBREX	5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U19		
		5760068	JUN 02, 2015	U299		
		5972986	OCT 14, 2017	U299		
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530 5177080	JUN 26, 2011 JAN 26, 2011		D-59 I-303	JUL 21, 2003 JUL 21, 2003
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NS	JUL 21, 2003
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358*PED	DEC 25, 2007		NPP	OCT 21, 2005
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358*PED	DEC 25, 2007		NPP	OCT 21, 2005
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U295	PED	APR 21, 2006
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358*PED	DEC 25, 2007	U295		
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	6469009	JUL 13, 2019	U295		
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	6489329	APR 08, 2016			
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
021197 001	CETRORELIX;CETROTIDE	5198533	JUL 17, 2007			
021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U426		
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
021197 002	CETRORELIX;CETROTIDE	5198533	JUL 17, 2007			
021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U426		
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4312860	AUG 20, 2003			
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4826821	MAY 02, 2006			
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	5110806	MAY 02, 2006			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	5340821	AUG 23, 2011	U309		
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	5580880	JUN 06, 2015	U310		
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP SEPP				NP	OCT 07, 2005
020774 001	CHLORHEXIDINE GLUCONATE;PERIOCHIP	5002769 5023082	MAR 16, 2006 MAR 30, 2005			
021441 001	CHLORPHENIRAMINE MALEATE;ADVIL ALLERGY SINUS				NP	DEC 19, 2005
019746 002	CHLORPHENIRAMINE MALEATE;EFIDAC 24	4857330	AUG 15, 2006			
019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
019574 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4933360	JUN 12, 2007			
021149 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	5767251	JUN 16, 2015		NP	SEP 20, 2003
021159 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX				NDF	FEB 28, 2006
021022 001	CICLOPIROX;LOPROX	4957730	SEP 18, 2007	U379		
020638 001	CICLOPIROX;LOPROX	5142051	JUN 26, 2010			
020863 001	CICLOPIROX;LOPROX				NCE	JAN 15, 2004
020863 002	CICLOPIROX;LOPROX				NCE	JAN 15, 2004
019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444*PED	JUN 09, 2004			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U223		
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444*PED	JUN 09, 2004	U223		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444*PED	JUN 09, 2004			
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754*PED	AUG 15, 2011			
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444*PED	JUN 09, 2004			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444*PED	JUN 09, 2004			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754*PED	AUG 15, 2011			



PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444 5286754 4670444*PED 5286754*PED	DEC 09, 2003 FEB 15, 2011 JUN 09, 2004 AUG 15, 2011	U36		
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC	4670444 4844902 4670444*PED	DEC 09, 2003 FEB 11, 2008 JUN 09, 2004			
019847 001	CIPROFLOXACIN; CIPRO	4670444 4705789 4808583 4670444*PED 4705789*PED 4808583*PED	DEC 09, 2003 NOV 10, 2004 FEB 28, 2006 JUN 09, 2004 MAY 10, 2005 AUG 28, 2006			
020780 001	CIPROFLOXACIN; CIPRO	5695784 4670444 6136347 4670444*PED 5695784*PED 6136347*PED	DEC 09, 2014 DEC 09, 2003 JAN 06, 2013 JUN 09, 2004 JUN 09, 2015 JUL 06, 2013	U362		
020780 002	CIPROFLOXACIN; CIPRO	5695784 4670444 6136347 4670444*PED 5695784*PED 6136347*PED	DEC 09, 2014 DEC 09, 2003 JAN 06, 2013 JUN 09, 2004 JUN 09, 2015 JUL 06, 2013	U362		
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444 4705789 4957922 4808583 4670444*PED 4705789*PED 4808583*PED 4957922*PED	DEC 09, 2003 NOV 10, 2004 SEP 18, 2007 FEB 28, 2006 JUN 09, 2004 MAY 10, 2005 AUG 28, 2006 MAR 18, 2008			
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444 4705789 4957922 4808583	DEC 09, 2003 NOV 10, 2004 SEP 18, 2007 FEB 28, 2006			
021473 001	CIPROFLOXACIN; CIPRO XR	4670444 4670444*PED	DEC 09, 2003 JUN 09, 2004		NDF PED	DEC 13, 2005 JUN 13, 2006
021473 002	CIPROFLOXACIN; CIPRO XR				NDF PED I-416 PED	DEC 13, 2005 JUN 13, 2006 AUG 28, 2006 FEB 28, 2007
021537 001	CIPROFLOXACIN; CIPRODEX	4844902 6284804 6359016	FEB 11, 2008 AUG 10, 2020 AUG 10, 2020		NC	JUL 18, 2006
020210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U79		
020210 002	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U79		
020398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U79		
020767 001	CISAPRIDE MONOHYDRATE; PROPULSID QUICKSOLV	4962115 5648093	OCT 09, 2007 JUL 15, 2014	U79		
020551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012	U127		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U127		
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U127		
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021535 001	CLOBETASOL PROPIONATE;CLOBEX	6106848	SEP 22, 2017		NDF	JUL 24, 2006
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM	6126920	OCT 03, 2017	U484	I-374	DEC 20, 2005
020615 001	CLONIDINE HYDROCHLORIDE;DURACLON				ODE	OCT 02, 2003
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003		I-349	FEB 27, 2005
		4847265	NOV 17, 2011			
		5576328	JAN 31, 2014	U432		
		6429210	JUN 10, 2019			
		6504030	JUN 10, 2019			
019758 001	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
019758 002	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5679717	APR 29, 2014	U323	NCE	MAY 26, 2005
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U323		
		5917007	APR 29, 2014	U323		
		5919832	JUN 10, 2014			
		6433026	JUN 10, 2014			
		6066678	JUN 10, 2014	U323		
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U323		
		5607669	JUN 10, 2014	U323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U323		
		6433026	JUN 10, 2014			
		6066678	JUN 10, 2014	U323		
		4724231	APR 16, 2005	U157		
019722 001	CYANOCOBALAMIN;NASCOBAL				D-78	FEB 03, 2006
017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL				ODE	APR 01, 2006
021041 001	CYTARABINE;DEPOCYT				D-60	AUG 03, 2003
020287 001	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-414	DEC 10, 2006
					I-414	DEC 10, 2006
020287 002	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
020287 003	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-414	DEC 10, 2006
					D-60	AUG 03, 2003
020287 004	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		I-414	DEC 10, 2006
					D-60	AUG 03, 2003
					I-414	DEC 10, 2006
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
021572 001	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
021572 002	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020705 002	DELAVIRDINE MESYLATE; RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			
020118 001	DESFLURANE; SUPRANE	4762856	FEB 02, 2007	U67		
021271 001	DESIRUDIN; IPRIVASK	4745177	MAY 17, 2005			
		4801576	JAN 31, 2006			
		5733874	MAR 31, 2015			
021165 001	DESLORATADINE; CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4863931	SEP 15, 2008		PED	JUN 21, 2007
		4804666	FEB 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		6100274	JUL 07, 2019			
		4659716*PED	OCT 21, 2004	U427		
		4804666*PED	AUG 14, 2006	U428		
		4863931*PED	MAR 15, 2009			
		5595997*PED	JUN 30, 2015	U429		
		6100274*PED	JAN 07, 2020			
021312 001	DESLORATADINE; CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4659716*PED	OCT 21, 2004	U427	PED	JUN 21, 2007
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		4804666	FEB 14, 2006	U428		
		4804666*PED	AUG 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		5595997*PED	JUN 30, 2015	U429		
		6100274	JUL 07, 2019			
		6100274*PED	JAN 07, 2020			
017922 001	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE; DDAVP (NEEDS NO REFRIGERATION)	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5763407	JUN 29, 2013			
021090 001	DESOGESTREL; CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
		4544554	SEP 26, 2003			
		4628051	SEP 26, 2003			
020713 001	DESOGESTREL; MIRCETTE	RE35724	OCT 20, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U421	NCE	DEC 17, 2004
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U339		
		4963551	DEC 21, 2007			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U339		
		4963551	DEC 21, 2007			
019082 001	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 002	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 003	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
020648 001	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 002	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U392		
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U392		
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U239		
		5653972	NOV 16, 2014	U239		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U402		
		5985850	NOV 16, 2016			
020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020154 005	DIDANOSINE;VIDEX	5880106*PED	JAN 22, 2012			
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
		4861759	AUG 29, 2006	U248		
020154 006	DIDANOSINE;VIDEX	5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
020155 003	DIDANOSINE;VIDEX	4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
020155 004	DIDANOSINE;VIDEX	5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
020155 005	DIDANOSINE;VIDEX	4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U248		
020155 006	DIDANOSINE;VIDEX	5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U52		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020156 001	DIDANOSINE;VIDEX	5254539	AUG 29, 2006	U248		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		4861759	AUG 29, 2006	U248		
		5254539	AUG 29, 2006	U180		
		5616566*PED	MAR 01, 2007	U180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
021183 004	DIDANOSINE;VIDEX EC	5254539*PED	MAR 01, 2007	U248		
		4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5169849	DEC 08, 2009	U227		
020062 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5470584	MAY 20, 2011			
020062 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5364620	NOV 14, 2011	U3		
		5439689	AUG 08, 2012	U107		
		5002776	MAR 26, 2008			
020062 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5364620	NOV 14, 2011	U3		
		5470584	MAY 20, 2011			
020062 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U3		
		5470584	MAY 20, 2011			
021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5364620	NOV 14, 2011	U3		
		5439689	AUG 08, 2012	U107		
		5470584	MAY 20, 2011			
021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
		5288505	JUN 26, 2011		NDF	FEB 06, 2006
021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5529791	JUN 25, 2013			
		5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
		5288505	JUN 26, 2011		NDF	FEB 06, 2006
021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5529791	JUN 25, 2013			
		5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
019471 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
		4721619	JAN 26, 2005			
		4721619	JAN 26, 2005			
020092 001	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4721619	JAN 26, 2005			
		4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 002	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
		4839177	DEC 09, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020092 003	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020507 001	DILTIAZEM MALATE;TECZEM	4968507	JUL 25, 2006			
		4880631	SEP 24, 2007			
		4983598	JAN 08, 2008			
020506 001	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 002	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 003	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
021191 001	DIMYRISTOYL LECITHIN;IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
		6280705	JUL 30, 2013			
		6287539	JUL 30, 2013			
		5605673	FEB 25, 2014			
		5626833	MAY 16, 2014	U458		
		5639443	JUN 17, 2014			
		5695741	DEC 09, 2014	U458		
		5720938	FEB 24, 2015			
		5798091	AUG 25, 2015	U458		
020411 001	DINOPROSTONE;CERVIDIL	4931288	JAN 16, 2007			
		5269321	DEC 14, 2010	U110		
019617 001	DINOPROSTONE;PREPIDIL	4680312	JUL 14, 2004			
018723 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 002	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 003	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019680 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019794 001	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
019794 002	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
		4913906	APR 03, 2007			
		6419953	DEC 18, 2018			
		6511678	DEC 18, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
		4988731	JAN 29, 2008			
		6511678	DEC 18, 2018			
020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-379	NOV 27, 2005
		5438072	NOV 22, 2013			
		5698582	JUL 03, 2012			
		5714512	JUL 03, 2012			
020941 001	DOCOSANOL;ABREVA	4874794	APR 28, 2014		NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 003	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U103		
		4619939	OCT 28, 2003	U104		
		6248735	APR 17, 2011			
		4619939*PED	APR 28, 2004			
		4797413*PED	OCT 28, 2008			
020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U103		
		4619939	OCT 28, 2003	U104		
		4619939*PED	APR 28, 2004			
		4797413*PED	OCT 28, 2008			
019946 001	DOXACURIUM CHLORIDE;NUROMAX	4701460	MAR 06, 2005			
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U278	NCE	JUN 09, 2004
		5707980	AUG 17, 2010	U278		
		5861386	AUG 02, 2008	U278		
		5869473	AUG 02, 2008	U278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U321	NCE	JUN 09, 2004
		5707980	AUG 17, 2010	U321		
050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
021098 001	DROSPIRENONE;YASMIN	5569652	OCT 29, 2013	U1	NC	MAY 11, 2004
021319 001	DUTASTERIDE;AVODART	5565467	OCT 15, 2013		NCE	NOV 20, 2006
		5846976	DEC 08, 2015	U476		
		5998427	OCT 15, 2013	U477		
020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U257		
		6238695	APR 06, 2019			
		6555133	APR 06, 2019	U248		
		6639071	FEB 14, 2018	DS		



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U257		
		6238695	APR 06, 2019			
		6555133	APR 06, 2019	U248		
020972 003	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018	DS	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U257		
		5811423	AUG 07, 2012	U256		
		6238695	APR 06, 2019			
021360 001	EFAVIRENZ;SUSTIVA	6555133	APR 06, 2019		NCE	SEP 17, 2003
		6639071	FEB 14, 2018	DS		
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014			
		5811423	AUG 07, 2012	U256		
021360 002	EFAVIRENZ;SUSTIVA	6639071	FEB 14, 2018	DS	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U248		
		5811423	AUG 07, 2012	U256		
		6639071	FEB 14, 2018	DS		
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4720489	JAN 19, 2005		NP	JUL 27, 2003
		5648394	JUL 15, 2014	U334		
		5545644	AUG 13, 2013			
		5545644	AUG 13, 2013			
		4430343	AUG 14, 2005	U403		
021500 001	EMTRICITABINE;EMTRIVA	5441958	DEC 08, 2013	U404	NCE	JUL 02, 2008
		5210085	MAY 11, 2010			
		5814639	SEP 29, 2015			
		5914331	SEP 29, 2015			
		6642245	NOV 04, 2020	U541		
020668 001	ENALAPRIL MALEATE;LEXXEL	4803081	APR 03, 2007		U3	
		4703038	OCT 07, 2005			
		4803081*PED	OCT 03, 2007			
		4703038	OCT 07, 2005			
		4803081	APR 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4803081*PED	OCT 03, 2007		U3	
		4703038	OCT 07, 2005			
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7 PED	FEB 13, 2004 AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7 PED	FEB 13, 2004 AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7 PED	FEB 13, 2004 AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7 PED	FEB 13, 2004 AUG 13, 2004
021481 001	ENFUVRTIDE;FUZEON	5464933	JUN 07, 2013		NCE	MAR 13, 2008
		6133418	JUN 07, 2013			
		6475491	JUN 07, 2015	U248		
		4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
020164 001	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
		4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
		4692435	DEC 24, 2004	DS DP U123		
020164 002	ENOXAPARIN SODIUM;LOVENOX	5389618	FEB 14, 2012	DS DP U545	I-315	NOV 17, 2003
		4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
		4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
020164 003	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
		4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
		4692435	DEC 24, 2004	DS DP U123		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020164 004	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 005	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 006	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
020164 007	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 008	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 009	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020796 001	ENTACAPONE; COMTAN	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		5112861	MAY 12, 2009			
		6599530	SEP 14, 2018	DP		
021565 001	EPINASTINE HYDROCHLORIDE; ELESTAT				NCE	OCT 15, 2008
050778 001	EPIRUBICIN HYDROCHLORIDE; ELLENCE				ODE	SEP 15, 2006
021437 001	EPLERENONE; INSPRA	4559332	APR 09, 2004	U537	NCE	SEP 27, 2007
		6410054	DEC 08, 2019	U3	I-407	OCT 07, 2006
		6410524	NOV 05, 2019	U467		
		6558707	DEC 08, 2009	DP U537		
		6534093	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U3		
021437 002	EPLERENONE; INSPRA	6410524	NOV 05, 2019	U467	NCE	SEP 27, 2007
		4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6534093	DEC 08, 2019	U3		
		6558707	DEC 08, 2009	DP U537		
		6495165	DEC 08, 2019	U3		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U537		
		6410054	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
021437 003	EPLERENONE; INSPRA	6410524	NOV 05, 2019	U467	NCE	SEP 27, 2007
		4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	DP U537		
		6410054	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U3		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6534093	DEC 08, 2019	U537		
020444 001	EPOPROSTENOL SODIUM; FLOLAN	4883812	MAY 12, 2006	U185	ODE	APR 14, 2007
020444 002	EPOPROSTENOL SODIUM; FLOLAN	4883812	MAY 12, 2006	U185	ODE	APR 14, 2007
020738 004	EPROSARTAN MESYLATE; TEVETEN	5656650	AUG 12, 2014	U3		
		5185351	FEB 09, 2010	U3		
020738 005	EPROSARTAN MESYLATE; TEVETEN	5656650	AUG 12, 2014	U3		
		5185351	FEB 09, 2010	U3		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020738 006	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U3		
		5656650	AUG 12, 2014	U3		
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U3		
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U3		
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		D-66	JUN 08, 2004
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U244		
		5968902	JUN 02, 2015	U453		
		5747447	MAY 05, 2015			
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		D-66	JUN 08, 2004
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U244		
		5968902	JUN 02, 2015	U453		
		5747447	MAY 05, 2015			
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
		5952323	MAY 15, 2017			
021323 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021323 002	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021323 003	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021365 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		I-366	AUG 29, 2005
					PED	FEB 14, 2006
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 004	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019386 006	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 007	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6310094	JAN 12, 2021			
		6528540	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 005	ESMOLOL HYDROCHLORIDE;BREVIBLOC DOUBLE STRENGTH	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U373		
		4853230	APR 20, 2007	U373		
		5714504	FEB 03, 2015	U373		
		5877192	MAY 27, 2014	U373		
		5690960	NOV 25, 2014	U373		
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U469		
		4738974*PED	OCT 19, 2005	U373		
		4786505*PED	OCT 20, 2007	U373		
		4853230*PED	OCT 20, 2007	U373		
		5690960*PED	MAY 25, 2015	U373		
		5714504*PED	AUG 03, 2015	U373		
		5877192*PED	NOV 27, 2014	U373		
		5900424*PED	NOV 04, 2016	U373		
		6147103	OCT 09, 2018			
		6147103*PED	APR 09, 2019			
6166213*PED	APR 09, 2019					
6191148*PED	APR 09, 2019					
6369085*PED	NOV 25, 2018					
6428810*PED	MAY 03, 2020	U469				
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U373		
		4853230	APR 20, 2007	U373		
		5714504	FEB 03, 2015	U373		
		5877192	MAY 27, 2014	U373		
		5690960	NOV 25, 2014	U373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U469		
		4738974*PED	OCT 19, 2005	U373		
		4786505*PED	OCT 20, 2007	U373		
		4853230*PED	OCT 20, 2007	U373		
		5690960*PED	MAY 25, 2015	U373		
		5714504*PED	AUG 03, 2015	U373		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5877192*PED	NOV 27, 2014	U373		
		5900424*PED	NOV 04, 2016	U373		
		6147103*PED	APR 09, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		6369085*PED	NOV 25, 2018			
		6428810*PED	MAY 03, 2020	U469		
021367 001	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
021367 002	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLA	RE36247	MAY 02, 2006			
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020375 001	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 002	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 005	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 006	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
021258 001	ESTRADIOL;CLIMARA PRO	5252334	OCT 12, 2010	DP	NC	NOV 21, 2006
		5770219	OCT 12, 2010	DP		
		5393529	FEB 28, 2012	DP		
		5676968	OCT 14, 2014	DP		
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U306		
		5188835	JUN 12, 2007	U306		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020417 001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
021040 001	ESTRADIOL;PREFEST	5108995	APR 28, 2009	U311		
		5382573	JAN 17, 2012			
020323 001	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 002	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 003	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 004	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
		5300291	APR 05, 2011		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020992 001	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		I-359	JUN 21, 2005
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012		D-82	JUL 16, 2006
004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 006	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012		D-82	JUL 16, 2006

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
		5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006			
020527 001	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015		D-79	MAR 12, 2006
		RE36247	MAY 02, 2006	U284		
		5210081	FEB 26, 2012			
020527 003	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015		D-79	MAR 12, 2006
		RE36247	MAY 02, 2006	U284		
		5210081	FEB 26, 2012			
020527 004	ESTROGENS, CONJUGATED;PREMPRO	RE36247	MAY 02, 2006		NP	MAR 12, 2006
		5547948	JAN 17, 2015		D-79	MAR 12, 2006
		5210081	FEB 26, 2012		D-81	JUN 04, 2006
020527 005	ESTROGENS, CONJUGATED;PREMPRO	5210081	FEB 26, 2012		NS	JUN 04, 2006
		RE36247	MAY 02, 2006		D-81	JUN 04, 2006
		5547948	JAN 17, 2015			
020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN)	5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006	U284		
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	4962098	OCT 09, 2007	U112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	4962098	OCT 09, 2007	U112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021187 001	ETHINYL ESTRADIOL;NUVARING	5989581	APR 08, 2018		NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	5876746	JUN 07, 2015	U514	NP	NOV 20, 2004
		5972377	JUN 07, 2015	U514		
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U66		
		4616006	SEP 26, 2003	U66		
		4628051	SEP 26, 2003	U66		
		4530839	SEP 26, 2003	U112		
		4530839*PED	MAR 26, 2004			
		4544554*PED	MAR 26, 2004			
		4616006*PED	MAR 26, 2004			
		4628051*PED	MAR 26, 2004			
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U66		
		4616006	SEP 26, 2003	U66		
		4628051	SEP 26, 2003	U66		
		4530839	SEP 26, 2003	U112		
021241 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN LO	4616006	SEP 26, 2003	U112	NP	AUG 22, 2005
		6214815	JUN 09, 2019	U112	PED	FEB 22, 2006
		4530839	SEP 26, 2003	U112		
		4544554	SEP 26, 2003	U112		
		4628051	SEP 26, 2003	U112		
		4530839*PED	MAR 26, 2004			
		4544554*PED	MAR 26, 2004			
		4616006*PED	MAR 26, 2004			
		4628051*PED	MAR 26, 2004			
		6214815*PED	DEC 09, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
018985 001	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-21	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018985 002	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-28	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
021490 001	ETHINYL ESTRADIOL;OVCON-35				NDF	NOV 14, 2006
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CONTRACEPTIVE KI	6156742	DEC 05, 2020	U374		
021544 001	ETHINYL ESTRADIOL;SEASONALE	5898032	JUN 23, 2017	U1	NP	SEP 05, 2006
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
		4904650	JUL 07, 2006		ODE	OCT 21, 2006
021445 001	EZETIMIBE;ZETIA	5846966	SEP 21, 2013	U474	NCE	OCT 25, 2007
		RE37721	JUN 16, 2015	U473		
020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020363 002	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015	U205		
		5854267	DEC 29, 2015	U267		
		5667794*PED	NOV 02, 2015	U205		
		5854267*PED	JUN 29, 2016	U267		
020325 002	FAMOTIDINE;PEPCID AC				NP	SEP 23, 2006
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U267		
		5075114	DEC 24, 2008			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
020902 001	FAMOTIDINE;PEPCID AC (GELTAB)	5854267	DEC 29, 2015	U368		
		5854267*PED	JUN 29, 2016	U368		
		5667794	MAY 02, 2015	U368		
		5667794*PED	NOV 02, 2015	U368		
		4820524	FEB 20, 2007			
		4820524*PED	AUG 20, 2007			
020189 001	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		
020189 002	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		
020189 003	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019834 001	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 002	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 004	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
		6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
		6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020195 001	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 002	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 003	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 007	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
021626 001	FERRIC HEXACYANOFERRATE (II);RADIOGARDASE (PRUSSIAN BLUE)				ODE	OCT 02, 2010
					NCE	OCT 02, 2008
020416 001	FERUMOXIDES;FERIDEX I.V.	4951675	AUG 28, 2007	U143		
		5102652	FEB 06, 2009			
		5248492	SEP 28, 2010			
		4770183	SEP 13, 2005	U145		
		4827945	MAY 09, 2006	U144		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020410 001	FERUMOXASIL;GASTROMARK	5055288	OCT 08, 2008			
		5219554	JUN 15, 2010			
		5069216	MAY 09, 2006	U171		
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U170		
		4951675	SEP 13, 2005	U169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U169		
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U192	M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U192		
		5738872*PED	AUG 28, 2015			
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6399632*PED	NOV 11, 2012	U468		
		5578610	NOV 26, 2013	U139	PED	AUG 25, 2003
		5932247	FEB 28, 2015		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	PED	AUG 25, 2003
		5932247	FEB 28, 2015		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES		
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U139	PED	AUG 25, 2003		
		5932247	FEB 28, 2015		M-25	MAY 12, 2006		
		5855912	FEB 28, 2015		PED	NOV 12, 2006		
		6037353	MAR 14, 2017	U138				
		6113942	FEB 28, 2015					
		6187791	MAY 11, 2012	U138				
		6399632	MAY 11, 2012	U468				
		5578610*PED	MAY 26, 2014	U139				
		5855912*PED	AUG 28, 2015					
		5932247*PED	AUG 28, 2015					
		6037353*PED	SEP 14, 2017	U138				
		6113942*PED	AUG 28, 2015					
		6187791*PED	NOV 11, 2012	U138				
		6399632*PED	NOV 11, 2012	U468				
		020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	5578610	NOV 26, 2013		M-25	MAY 12, 2006
5855912	FEB 28, 2015				PED	NOV 12, 2006		
6037353	MAR 14, 2017			U138				
6039974	JUL 31, 2018							
6113942	FEB 28, 2015							
6187791	MAY 11, 2012			U138				
6399632	MAY 11, 2012			U468				
5578610*PED	MAY 26, 2014							
5855912*PED	AUG 28, 2015							
6037353*PED	SEP 14, 2017			U138				
6113942*PED	AUG 28, 2015							
6187791*PED	NOV 11, 2012			U138				
6399632*PED	NOV 11, 2012			U468				
020788 001	FINASTERIDE; PROPECIA			4760071	JUN 19, 2006			
				5571817	NOV 05, 2013	U259		
		5547957	OCT 15, 2013	U236				
		5886184	NOV 19, 2012					
		4760071	JUN 19, 2006	U262				
020180 001	FINASTERIDE; PROSCAR	5886184	NOV 19, 2012					
		5942519	OCT 23, 2018	U280				
		6046183	MAR 20, 2011					
018830 001	FLECAINIDE ACETATE; TAMBOCOR	4642384	FEB 10, 2004					
018830 002	FLECAINIDE ACETATE; TAMBOCOR	4642384	FEB 10, 2004					
018830 003	FLECAINIDE ACETATE; TAMBOCOR	4642384	FEB 10, 2004					
018830 004	FLECAINIDE ACETATE; TAMBOCOR	4642384	FEB 10, 2004					
019949 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
019949 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
019949 003	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
019949 004	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
020090 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
020090 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004					
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004					
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004					
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004					
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004					
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004					
020038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324*PED	AUG 24, 2003					
020073 001	FLUMAZENIL; ROMAZICON	4316839	OCT 10, 2004					

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
018340 001	FLUNISOLIDE;AEROBID	4933168	JUN 12, 2007			
018148 001	FLUNISOLIDE;NASALIDE	4933168	JUN 12, 2007			
020409 001	FLUNISOLIDE;NASAREL	4782047	MAY 22, 2006			
		4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005		NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U338	PED	JAN 06, 2004
					D-75	JUN 12, 2005
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U338	PED	JAN 06, 2004
					D-75	JUN 12, 2005
021520 002	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 003	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 004	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 005	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387		
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
		4335121*PED	MAY 14, 2004			
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387	I-410	NOV 17, 2006
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5290815	MAR 01, 2011	U386		
		4335121*PED	MAY 14, 2004			
		4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387		
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121*PED	MAY 14, 2004			
		4335121	NOV 14, 2003			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121*PED	MAY 14, 2004			
		4335121	NOV 14, 2003			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121*PED	MAY 14, 2004			
		4335121	NOV 14, 2003		D-76	MAY 23, 2005
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121*PED	MAY 14, 2004			
		4335121	NOV 14, 2003		PED	NOV 23, 2005
		4335121*PED	MAY 14, 2004		M-24	MAY 01, 2006
		4335121	NOV 14, 2003		PED	NOV 01, 2006
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U109	I-394	MAY 27, 2006
		5356896	DEC 12, 2011			
		5354772	OCT 11, 2011	U413		
		5356896	DEC 12, 2011	U109	I-394	MAY 27, 2006
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U413		
		5356896	DEC 12, 2011	U109	I-394	MAY 27, 2006
		5354772	OCT 11, 2011	U413		
		5356896	DEC 12, 2011	U413	NDF	OCT 06, 2003
021192 001	FLUVASTATIN SODIUM;LESCOL XL	6242003	APR 13, 2020		I-394	MAY 27, 2006
		5354772	OCT 11, 2011	U109		
		5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U206		
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
		5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U206		
		5767251	JUN 16, 2015			
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			
020696 001	FOMEPIZOLE;ANTIZOL				ODE ODE I-319	DEC 04, 2004 DEC 08, 2007 DEC 08, 2003
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE	5442049	AUG 15, 2012		NCE	AUG 26, 2003
		5595978	AUG 15, 2012	U522		
		4689320	OCT 15, 2004	U522		
		5264423	NOV 23, 2010	U522		
		5276019	JAN 04, 2011	U522		
021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003		NCE I-397	DEC 07, 2006 JUN 17, 2006
020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019		NCE I-342 NPP	FEB 16, 2006 SEP 25, 2004 JUN 27, 2006
021279 001	FORMOTEROL FUMARATE;FORADIL				I-342 NCE	SEP 25, 2004 FEB 16, 2006
021548 001	FOSAMPRENAVIR CALCIUM;LEXIVA	6436989	DEC 24, 2017	U257	NE	OCT 20, 2006
		6514953	JUL 15, 2019	U257		
076139 001	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
076139 002	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
076139 003	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
019915 002	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
019915 003	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
019915 004	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4925860	AUG 05, 2007		ODE	AUG 05, 2003
021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U436	NCE	NOV 08, 2006
		5616603	APR 01, 2014	U436		
		5637611	JUN 10, 2014	U436		
		5827871	OCT 27, 2015	U436		
		5962501	DEC 16, 2013	U436		
021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
020235 001	GABAPENTIN;NEURONTIN	4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
		4894476	MAY 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020882 001	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
021129 001	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020123 001	GADODIAMIDE; OMNISCAN	4687659	MAY 04, 2007	U76		
		4647447	MAR 03, 2004			
		4963344	MAR 03, 2004			
		4957939	MAR 03, 2004			
019596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
021037 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4963344	MAR 03, 2004			
		4885363	DEC 05, 2006			
		5474756	DEC 12, 2012	U480		
		5846519	DEC 08, 2015			
021489 001	GADOTERIDOL; PROHANCE MULTIPACK	6143274	DEC 12, 2012	U480		
		5474756	DEC 12, 2012	U536		
		6143274	DEC 12, 2012	U536		
		4885363	DEC 05, 2006			
020937 001	GADOVERSETAMIDE; OPTIMARK	5846519	DEC 08, 2015			
		5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
		5130120	JUL 14, 2009			
020975 001	GADOVERSETAMIDE; OPTIMARK	5137711	JUL 14, 2009			
		5137711	JUL 14, 2009		NCE	DEC 08, 2004
		5130120	JUL 14, 2009			
		5137711	JUL 14, 2009			
020976 001	GADOVERSETAMIDE; OPTIMARK	5130120	JUL 14, 2009			
		5137711	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
		5130120	JUL 14, 2009			
021169 001	GALANTAMINE HYDROBROMIDE; REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 002	GALANTAMINE HYDROBROMIDE; REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 003	GALANTAMINE HYDROBROMIDE; REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021224 001	GALANTAMINE HYDROBROMIDE; REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
019961 002	GALLIUM NITRATE; GANITE	4529593	JAN 17, 2005	U49		
020460 001	GANCICLOVIR; CYTOVENE	4642346	JUN 24, 2005			
020460 002	GANCICLOVIR; CYTOVENE	4642346	JUN 24, 2005			
076457 001	GANCICLOVIR; GANCICLOVIR				PC	FEB 16, 2004
076457 002	GANCICLOVIR; GANCICLOVIR				PC	FEB 16, 2004
020569 001	GANCICLOVIR; VITRASERT	5378475	JAN 03, 2012			
021057 001	GANIRELIX ACETATE; ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		I-329	OCT 17, 2005
		5880283	DEC 05, 2015		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		D-69	OCT 12, 2004
		5880283	DEC 05, 2015		I-329	OCT 17, 2005
021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
021062 003	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		I-329	OCT 17, 2005
		5880283	DEC 05, 2015		NCE	DEC 17, 2004
021062 004	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		D-69	OCT 12, 2004
		5880283	DEC 05, 2015		I-329	OCT 17, 2005
021493 001	GATIFLOXACIN; ZYMAR	5880283	DEC 05, 2015		NDF	MAR 28, 2006
		4980470	DEC 15, 2009		NCE	DEC 17, 2004
021399 001	GEFITINIB; IRESSA	5457105	JAN 19, 2013		NCE	MAY 05, 2008
		5616582	JAN 19, 2013			
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	5770599	APR 26, 2016			
		4808614	MAY 15, 2010		U146	
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012		U146	
		4808614	MAY 15, 2010			
021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6262071	SEP 21, 2019		U513	NCE
		6331550	SEP 21, 2019		U511	APR 04, 2008
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	6340689	SEP 14, 2019		U512	
		6455540	SEP 21, 2019		U511	
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5633262	JUN 15, 2015			
		5776944	JUN 15, 2015			
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5962468	JUN 15, 2015		U282	
		5606040	FEB 25, 2014			ODE
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5693762	DEC 02, 2014			NCE
		5739116	APR 14, 2015			
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5767285	JUN 16, 2015			
		5773001	JUN 30, 2015		U320	
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
020622 001	GLATIRAMER ACETATE;COPAXONE	5585089	DEC 17, 2013			
		5981589	MAY 24, 2014			ODE
020622 001	GLATIRAMER ACETATE;COPAXONE	6054430	MAY 24, 2014			DEC 20, 2003
		6342476	MAY 24, 2014		U441	
020622 001	GLATIRAMER ACETATE;COPAXONE	6362161	MAY 24, 2014		U441	
		6620847	MAY 24, 2014		DS	
020622 002	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014			ODE
		6054430	MAY 24, 2014			DEC 20, 2003
020622 002	GLATIRAMER ACETATE;COPAXONE	6342476	MAY 24, 2014		U441	
		6362161	MAY 24, 2014		U441	
020622 002	GLATIRAMER ACETATE;COPAXONE	6620847	MAY 24, 2014		DS	
		6620847	MAY 24, 2014			



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
076467 001	GLIPIZIDE;GLIPIZIDE				PC	OCT 19, 2003
020329 001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U150		
		5024843	SEP 05, 2009			
		5091190	SEP 05, 2009	U111		
		4612008	SEP 16, 2003			
		5082668	SEP 16, 2003			
		5545413	JUL 21, 2008	U111		
020329 002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U150		
		5082668	SEP 16, 2003			
		5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
020329 003	GLIPIZIDE;GLUCOTROL XL	4612008	SEP 16, 2003			
		5024843	SEP 05, 2009			
		5082668	SEP 16, 2003			
		5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
		5591454	JAN 07, 2014	U111		
021460 001	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 002	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 003	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
020051 001	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
020051 002	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 003	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 004	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
019726 001	GOSERELIN ACETATE;ZOLADEX	5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
020578 001	GOSERELIN ACETATE;ZOLADEX	4767628	AUG 30, 2005			
		5366734	NOV 22, 2011			
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U89	I-369	AUG 16, 2005
		6294548	MAY 04, 2019			
		5952340	SEP 14, 2016	U519		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808 6294548 5952340	DEC 29, 2007 MAY 04, 2019 SEP 14, 2016	U89 U519	I-369	AUG 16, 2005
020305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U105		
020305 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 20, 2007	U105		
021238 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U105		
020695 001	GREPAFLOXACIN HYDROCHLORIDE; RAXAR	5563138	OCT 08, 2013			
021282 001	GUAIFENESIN; MUCINEX	6372252	APR 28, 2020	U489		
021282 002	GUAIFENESIN; MUCINEX	6372252	APR 28, 2020	U489		
019967 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 16, 2004			
019968 001	HALOBETASOL PROPIONATE; ULTRAVATE	4619921	DEC 16, 2004			
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450 4743450*PED	FEB 24, 2007 AUG 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450 4743450*PED	FEB 24, 2007 AUG 24, 2007			
020125 003	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450 4743450*PED	FEB 24, 2007 AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE; AVALIDE	5270317 5994348	SEP 30, 2011 JUN 07, 2015			
020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317 5994348	SEP 30, 2011 JUN 07, 2015			
020758 003	HYDROCHLOROTHIAZIDE; AVALIDE	5270317 5994348	SEP 30, 2011 JUN 07, 2015			
021532 002	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 01, 2014	U500	NC NCE	JUN 05, 2006 APR 25, 2007
021532 003	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 01, 2014	U500	NC NCE	JUN 05, 2006 APR 25, 2007
021532 005	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 01, 2014	U500	NC NCE	JUN 05, 2006 APR 25, 2007
020818 001	HYDROCHLOROTHIAZIDE; DIOVAN HCT	5399578 6294197	MAR 21, 2012 JUN 18, 2017	U3		
020818 002	HYDROCHLOROTHIAZIDE; DIOVAN HCT	5399578 6294197	MAR 21, 2012 JUN 18, 2017	U3		
020818 003	HYDROCHLOROTHIAZIDE; DIOVAN HCT	5399578 6294197	MAR 21, 2012 JUN 18, 2017	U3		
020387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197 5138069 5608075 5138069*PED 5153197*PED 5608075*PED	OCT 06, 2009 AUG 11, 2009 MAR 04, 2014 FEB 11, 2010 APR 06, 2010 SEP 04, 2014	U538 U538	I-415	SEP 30, 2006
020387 002	HYDROCHLOROTHIAZIDE; HYZAAR	5153197 5138069 5153197 5153197*PED 5138069 5153197 5608075*PED 5608075*PED	OCT 06, 2009 AUG 11, 2009 OCT 06, 2009 APR 06, 2010 AUG 11, 2009 OCT 06, 2009 MAR 04, 2014 FEB 11, 2010 APR 06, 2010 SEP 04, 2014	U3 U3 U538 U538	I-415	SEP 30, 2006
021162 001	HYDROCHLOROTHIAZIDE; MICARDIS HCT	5153197 5153197*PED 5591762 6358986	OCT 06, 2009 APR 06, 2010 JAN 07, 2014 JAN 10, 2020	U3 U3 U3	NC	NOV 17, 2003

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U3	NC	NOV 17, 2003
		6358986	JAN 10, 2020			
020729 001	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U55		
		6348216	JUN 10, 2017			
		6599531	JUN 10, 2017			
020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
020453 001	HYDROCORTISONE PROBUTATE;PANDEL	4794106	AUG 28, 2006			
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
021455 001	IBANDRONATE SODIUM;BONIVA	4927814	JUL 09, 2007	U520	NCE	MAY 16, 2008
		6143326	APR 21, 2017	U520		
		6294196	OCT 07, 2019			
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007			
		4788220*PED	JAN 08, 2008			
021373 001	IBUPROFEN;CHILDREN'S ADVIL COLD				NP PED	AUG 01, 2003 FEB 01, 2004
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
021128 001	IBUPROFEN;CHILDREN'S MOTRIN COLD	6211246	JUN 10, 2019		NP	AUG 01, 2003
021472 001	IBUPROFEN;IBUPROFEN	6251426	JUN 25, 2018			
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020135 001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009			
021321 001	ICODEXTRIN;EXTRANEAL	6248726	JUN 19, 2018	U495	ODE	DEC 20, 2009
		4761237	AUG 02, 2005	U495		
		4886789	DEC 12, 2006	U495		
		6077836	JUN 20, 2017	U495		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019763 001	IFOSFAMIDE; IFEX	4882452	MAR 03, 2008			
019763 002	IFOSFAMIDE; IFEX	4882452	MAR 03, 2008			
019763 003	IFOSFAMIDE; IFEX/MESNEX KIT	4882452	MAR 03, 2008			
019763 004	IFOSFAMIDE; IFEX/MESNEX KIT	4882452	MAR 03, 2008			
021335 001	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
					I-392	MAY 20, 2006
021335 002	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
					I-392	MAY 20, 2006
021588 001	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
021588 002	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
					NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
020367 001	IMIGLUCERASE; CEREZYME	5549892	AUG 27, 2013	U252		
020367 002	IMIGLUCERASE; CEREZYME	5549892	AUG 27, 2013	U252		
020723 001	IMIQUIMOD; ALDARA	4689338	AUG 25, 2009	U172		
		5238944	AUG 24, 2010			
020685 001	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 003	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 005	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 006	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020986 001	INSULIN ASPART; NOVOLOG	5618913	APR 08, 2014		NCE	JUN 07, 2005
		5866538	JUN 20, 2017		NR	DEC 21, 2004
021172 001	INSULIN ASPART; NOVOLOG MIX 70/30	5547930	SEP 28, 2013		NC	NOV 01, 2004
		5834422	SEP 28, 2013	U471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U471		
		5618913	APR 08, 2014			
021081 001	INSULIN GLARGINE; LANTUS	5656722	SEP 12, 2014		PED	OCT 20, 2005
		5656722*PED	MAR 12, 2015		NCE	APR 20, 2005
					D-80	MAY 01, 2006
020563 001	INSULIN LISPRO; HUMALOG	5474978	JUN 16, 2014	U534		
		5514646	MAY 07, 2013	U534		
021018 001	INSULIN LISPRO; HUMALOG MIX 50/50	5461031	JUN 26, 2014			
		5474978	JUN 16, 2014			
		5514646	MAY 07, 2013			
		5747642	JUN 16, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014			
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014	U534		
		5514646	MAY 07, 2013	U534		
020351 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020808 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020351 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
020808 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
021425 001	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005	U498		
021425 002	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005	U498		
020220 004	IOPROMIDE;ULTRAVIST 150	4364921	MAR 06, 2005	U113		
020220 003	IOPROMIDE;ULTRAVIST 240	4364921	MAR 06, 2005	U113		
020220 002	IOPROMIDE;ULTRAVIST 300	4364921	MAR 06, 2005	U113		
020220 001	IOPROMIDE;ULTRAVIST 370	4364921	MAR 06, 2005	U113		
020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
		6403569	APR 28, 2020	U449		
040024 001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
018662 002	ISOTRETINOIN;ACUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 003	ISOTRETINOIN;ACUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 004	ISOTRETINOIN;ACUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
019546 001	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U3		
019546 002	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U3		
020336 001	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U3		
		4466972	AUG 21, 2003	U3		
		4783337	SEP 16, 2003	U3		
		4946687	AUG 07, 2007			
		5030456	JUL 09, 2008			
		4950486	AUG 21, 2007			
020336 002	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U3		
		4783337	SEP 16, 2003	U3		
		4946687	AUG 07, 2007			
		4466972	AUG 21, 2003	U3		
		4950486	AUG 21, 2007			
		5030456	JUL 09, 2008			
020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
020657 001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			
		6407079	JUN 18, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020966 001	ITRACONAZOLE; SPORANOX	4727064	FEB 23, 2005		I-332	MAY 09, 2004
		6407079	JUN 18, 2019			
020310 001	KETOCONAZOLE; NIZORAL A-D	5456851	APR 07, 2014			
019700 001	KETOROLAC TROMETHAMINE; ACULAR	5110493	MAY 05, 2009	U75	M-16	FEB 08, 2005
		5110493*PED	NOV 05, 2009	U75		
021528 001	KETOROLAC TROMETHAMINE; ACULAR LS	5110493	MAY 05, 2009		NP	MAY 30, 2006
		5110493*PED	NOV 05, 2009			
020811 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE FREE				M-16	FEB 08, 2005
021066 001	KETOTIFEN FUMARATE; ZADITOR				NCE	JUL 02, 2004
020857 001	LAMIVUDINE; COMBIVIR	4837208	SEP 17, 2005			
		5047407*PED	MAY 17, 2010			
		5905082*PED	NOV 18, 2016	U248		
		6113920	OCT 23, 2017	U257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	NOV 17, 2009			
		5859021	MAY 15, 2012	U248		
		5905082	MAY 18, 2016	U248		
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020564 001	LAMIVUDINE; EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020564 003	LAMIVUDINE; EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
		5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020596 001	LAMIVUDINE; EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		6004968	MAR 20, 2018			
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
021003 001	LAMIVUDINE; EPIVIR-HBV	5047407	NOV 17, 2009		I-339	AUG 16, 2004
		5532246	JUL 02, 2013	U250	PED	FEB 16, 2005
		5905082	MAY 18, 2016			
		5047407*PED	MAY 17, 2010			
		5532246*PED	JAN 02, 2014	U250		
		5905082*PED	NOV 18, 2016			
021004 001	LAMIVUDINE; EPIVIR-HBV	5047407	NOV 17, 2009		PED	FEB 16, 2005
		5532246	JUL 02, 2013	U250	I-339	AUG 16, 2004
		6004968	MAR 20, 2018			
		5047407*PED	MAY 17, 2010			
		5532246*PED	JAN 02, 2014	U250		
		6004968*PED	SEP 20, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020764 001	LAMOTRIGINE; LAMICTAL CD	5698226 4602017	JAN 29, 2012 JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020764 002	LAMOTRIGINE; LAMICTAL CD	5698226 4602017	JAN 29, 2012 JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020764 003	LAMOTRIGINE; LAMICTAL CD	5698226 4602017	JAN 29, 2012 JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 20, 2006
020764 004	LAMOTRIGINE; LAMICTAL CD	5698226 4602017	JAN 29, 2012 JUL 22, 2008	U106	ODE I-387 I-404	AUG 24, 2005 JAN 17, 2006 JUN 10, 2006
020406 001	LANSOPRAZOLE; PREVACID	5093132 5045321 4689333 5026560 4628098 5433959 5013743	SEP 03, 2008 SEP 03, 2008 JUL 29, 2005 JUN 25, 2008 MAY 10, 2009 SEP 03, 2008 FEB 12, 2010	U126	I-316 M-12	NOV 30, 2003 JUL 31, 2005
020406 002	LANSOPRAZOLE; PREVACID	4689333 5026560 5045321 5093132 4628098 5433959 5013743	JUL 29, 2005 JUN 25, 2008 SEP 03, 2008 SEP 03, 2008 MAY 10, 2009 SEP 03, 2008 FEB 12, 2010	U126	I-316 M-12	NOV 30, 2003 JUL 31, 2005
021281 001	LANSOPRAZOLE; PREVACID	4628098 4689333 5013743 5026560 5045321 5093132 5433959	MAY 10, 2009 JUL 29, 2005 FEB 12, 2010 JUN 25, 2008 SEP 03, 2008 SEP 03, 2008 SEP 03, 2008	U452 U126 U452	I-316	NOV 30, 2003
021281 002	LANSOPRAZOLE; PREVACID	4628098 4689333 5013743 5026560 5045321	MAY 10, 2009 JUL 29, 2005 FEB 12, 2010 JUN 25, 2008 SEP 03, 2008	U126 U452	I-316	NOV 30, 2003

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021428 001	LANSOPRAZOLE;PREVACID	5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
021428 002	LANSOPRAZOLE;PREVACID	6328994	MAY 17, 2009			
		4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U260	I-375	DEC 20, 2005
		5422368	MAR 22, 2011	U260		
		4599353	JUL 28, 2006	U260		
		6429226	SEP 06, 2009	U260		
020905 001	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
					I-395	JUN 13, 2006
					PED	MAR 10, 2004
020905 002	LEFLUNOMIDE;ARAVA				PED	DEC 13, 2006
					NCE	SEP 10, 2003
					I-395	JUN 13, 2006
020905 003	LEFLUNOMIDE;ARAVA				PED	MAR 10, 2004
					PED	DEC 13, 2006
					NCE	SEP 10, 2003
020807 001	LEPIRUDIN;REFLUDAN				I-395	JUN 13, 2006
					PED	MAR 10, 2004
					PED	DEC 13, 2006
020726 001	LETROZOLE;FEMARA				ODE	MAR 06, 2005
					I-318	JAN 10, 2004
021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014	U203	NP	JAN 23, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
		5599552	FEB 04, 2014			
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
021379 001	LEUPROLIDE ACETATE;ELIGARD	5324519	OCT 20, 2011		NP	JUL 24, 2005
		5599552	FEB 04, 2014			
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021488 001	LEUPROLIDE ACETATE; ELIGARD	4938763	OCT 03, 2008		NP	FEB 13, 2006
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
		5599552	FEB 04, 2014			
		5733950	OCT 03, 2008			
019732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5739176	OCT 03, 2008			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
020011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	6036976	DEC 13, 2013			
		5631020	NOV 01, 2004			
		5631021	MAY 20, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5643607	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	NOV 19, 2013			
		5480656	JAN 02, 2013			
		4849228	JUL 18, 2006			
		5330767	NOV 01, 2004			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		5330767	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
020263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
020263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
020263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
020708 001	LEUPROLIDE ACETATE; LUPRON DEPOT-3	5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
5476663	NOV 01, 2004					
5480656	JAN 02, 2013					

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5575987	NOV 19, 2013			
		5643607	JAN 02, 2013			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
		5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5330767	NOV 01, 2004			
		5643607	JAN 02, 2013			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
021088 001	LEUPROLIDE ACETATE;VIADUR	6036976	DEC 13, 2016			
		5728396	JAN 30, 2017	U316		
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
		6156331	JAN 30, 2017			
		6235712	JUN 13, 2017			
		6375978	DEC 17, 2018			
		6395292	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020837 003	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U42		
021035 001	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
021035 002	LEVETIRACETAM;KEPPRA	4837223	JUN 06, 2006			
		4943639	AUG 06, 2009		NCE	NOV 30, 2004
021035 003	LEVETIRACETAM;KEPPRA	4837223	JUN 06, 2006			
		4943639	AUG 06, 2009		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021505 001	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4837223 4911920 5540918	JUN 06, 2006 MAR 27, 2007 JUL 30, 2013	U369		
020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 07, 2004			
020182 001	LEVOCARNITINE;CARNITOR	6335369 6429230	JAN 18, 2021 JAN 18, 2021	U433 U433	ODE	DEC 15, 2006
020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020635 004	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-372 I-393 D-83	OCT 30, 2005 MAY 23, 2006 OCT 23, 2006
020635 005	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-393 I-372 D-83	MAY 23, 2006 OCT 30, 2005 OCT 23, 2006
021199 001	LEVOFLOXACIN;QUIXIN	4382892 5053407 4551456	SEP 02, 2003 DEC 20, 2010 NOV 14, 2003		NDF	AUG 18, 2003
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
021342 001	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 002	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 003	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 004	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 005	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 006	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021301 001	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 002	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 003	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021301 004	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 005	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 006	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 007	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 008	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 009	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 010	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 011	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 012	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
020575 001	LIDOCAINE;LIDOCAINE	5446070	FEB 27, 2011			
		5234957	FEB 27, 2011			
		5332576	JUL 26, 2011			
020575 002	LIDOCAINE;LIDOCAINE	5332576	JUL 26, 2011			
		5234957	FEB 27, 2011			
		5446070	FEB 27, 2011			
020612 001	LIDOCAINE;LIDODERM	5589180	MAR 17, 2009	U485	ODE	MAR 19, 2006
		5411738	MAY 02, 2012			
		5827529	OCT 27, 2015	U486		
		5709869	MAR 17, 2009	U485		
		5601838	MAY 02, 2012	U488		
021451 001	LIDOCAINE;ORAQIX				NDF	DEC 19, 2006
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
		6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
		6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
019558 001	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 002	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 003	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 004	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 006	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019777 001	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 002	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 003	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019777 004	LISINOPRIL; ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
019777 005	LISINOPRIL; ZESTRIL				NPP	MAY 29, 2006
					PED	AUG 07, 2003
					PED	NOV 29, 2006
019777 006	LISINOPRIL; ZESTRIL				NPP	MAY 29, 2006
					PED	AUG 07, 2003
					PED	NOV 29, 2003
					NPP	MAY 29, 2006
020191 001	LODOXAMIDE TROMETHAMINE;ALOMIDE	5457126	OCT 10, 2012	U117		
020013 001	LOMEFLOXACIN HYDROCHLORIDE;MAXAQUIN	4528287	FEB 21, 2006	U36		
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		5716641	MAY 21, 2012	U226		
021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5612054	SEP 28, 2010			
		5248505	SEP 28, 2010	U434		
		6103260	JUL 17, 2017			
021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U352		
		5541206	JUL 30, 2013	U348		
		5674882	OCT 07, 2014	U344		
		5886036	DEC 29, 2012	U345		
		6037157	JUN 26, 2016	U346		
		5846987	DEC 29, 2012	U350		
		5648497	JUL 15, 2014			
		6232333	NOV 07, 2017			
		6284767	FEB 14, 2016	U401		
		6458818	NOV 07, 2017			
		6521651	NOV 01, 2017			
021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U351		
		5635523	JUN 03, 2014	U352		
		5846987	DEC 29, 2012	U350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U344		
		5886036	DEC 29, 2012	U345		
		6037157	JUN 26, 2016	U346		
		6284767	FEB 14, 2016	U401		
019658 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
019658 002	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
		6132758	JUN 01, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
020641 002	LORATADINE; CLARITIN	4659716	APR 21, 2004	U142			
		4659716*PED	OCT 21, 2004	U142			
		4863931	SEP 15, 2008				
		4863931*PED	MAR 15, 2009				
		6132758	JUN 01, 2018				
020704 001	LORATADINE; CLARITIN REDITABS	4659716	APR 21, 2004	U142			
		4863931	SEP 15, 2008				
		4659716*PED	OCT 21, 2004	U142			
		4863931*PED	MAR 15, 2009				
		4659716	APR 21, 2004	U142			
020704 002	LORATADINE; CLARITIN REDITABS	4659716*PED	OCT 21, 2004	U142			
		4863931	SEP 15, 2008				
		4863931*PED	MAR 15, 2009				
		4659716	APR 21, 2004	U142			
		4659716*PED	OCT 21, 2004	U142			
019670 001	LORATADINE; CLARITIN-D	4863931	SEP 15, 2008				
		4863931*PED	MAR 15, 2009				
		4659716	APR 21, 2004	U142			
		4863931	SEP 15, 2008				
		4659716*PED	OCT 21, 2004	U142			
019670 002	LORATADINE; CLARITIN-D	4863931*PED	MAR 15, 2009				
		4659716	APR 21, 2004	U142			
		4659716*PED	OCT 21, 2004	U142			
		4863931	SEP 15, 2008				
		4863931*PED	MAR 15, 2009				
020470 001	LORATADINE; CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U142			
		5314697*PED	APR 23, 2013				
		4863931	SEP 15, 2008				
		4659716*PED	OCT 21, 2004	U142			
		4863931*PED	MAR 15, 2009				
020470 002	LORATADINE; CLARITIN-D 24 HOUR	5314697	OCT 23, 2012				
		4659716	APR 21, 2004	U142			
		4659716*PED	OCT 21, 2004	U142			
		4863931	SEP 15, 2008				
		4863931*PED	MAR 15, 2009				
075209 001	LORATADINE; LORATADINE	5314697	OCT 23, 2012				
		5314697*PED	APR 23, 2013				
						PC	JUL 21, 2003
						PC	AUG 09, 2003
						PC	NOV 29, 2003
075706 001	LORATADINE; LORATADINE AND PSEUDOEPHEDRINE SU					PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
076050 001	LORATADINE; LORATADINE AND PSEUDOEPHEDRINE SU					PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
						PC	JUL 30, 2003
020386 001	LOSARTAN POTASSIUM; COZAAR	5138069	AUG 11, 2009				
		5153197	OCT 06, 2009				
		5608075	MAR 04, 2014	U3			
		5138069*PED	FEB 11, 2010				
		5153197*PED	APR 06, 2010	U3			
020386 002	LOSARTAN POTASSIUM; COZAAR	5608075*PED	SEP 04, 2014				
		5210079	MAY 11, 2010	U496			
		5210079*PED	NOV 11, 2010	U496			
		5153197	OCT 06, 2009	U3	I-383	SEP 17, 2005	
		5138069	AUG 11, 2009				
		5608075	MAR 04, 2014				
		5138069*PED	FEB 11, 2010				
		5153197*PED	APR 06, 2010	U3			
		5608075*PED	SEP 04, 2014				
		5210079	MAY 11, 2010	U496			
		5210079*PED	NOV 11, 2010	U496			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009		I-383	SEP 17, 2005
		5153197	OCT 06, 2009	U3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U3		
		5608075*PED	SEP 04, 2014			
		5210079	MAY 11, 2010	U496		
		5210079*PED	NOV 11, 2010	U496		
		4996335	MAR 09, 2012			
		5540930	OCT 25, 2013			
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012			
		5540930	OCT 25, 2013			
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012			
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	5540930	OCT 25, 2013			
		4996335	FEB 26, 2008			
021249 001	LOVASTATIN;ADVICOR	5540930	OCT 25, 2013			
		6080428	MAY 27, 2017	U447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U448		
		6406715	OCT 31, 2017	U450		
021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U448		
		6406715	OCT 31, 2017	U450		
		6080428	MAY 27, 2017	U447		
021249 003	LOVASTATIN;ADVICOR	6129930	SEP 20, 2013	U448	NC	DEC 17, 2004
		6406715	OCT 31, 2017	U450		
		6080428	MAY 27, 2017	U447		
		6129930	SEP 20, 2013	U448		
021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
019643 003	LOVASTATIN;MEVACOR				I-350	FEB 14, 2005
					PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
					ODE	JUN 05, 2005
019832 003	MAFENIDE ACETATE;SULFAMYLON					
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011			
		4992554	FEB 12, 2008			
		5091169	FEB 25, 2009			
		5223243	JUN 29, 2010	U237		
		4647447	MAR 03, 2004	U238		
		4695590	APR 17, 2008			
		5008294	APR 15, 2008	U68		
019591 001	MEFLOQUINE HYDROCHLORIDE;LARIAM	4579855	OCT 01, 2004			
020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011			
020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
020938 002	MELOXICAM;MOBIC				NCE	APR 13, 2005
020207 001	MELPHALAN HYDROCHLORIDE;ALKERAN	4997651	NOV 18, 2008			
021487 001	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		



PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021487 002	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 003	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 004	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
020922 001	MEQUINOL; SOLAGE	5194247	MAR 16, 2010	U294	NC	DEC 10, 2004
		5470567	MAR 19, 2010	U294		
		6353029	AUG 24, 2020			
019651 001	MESALAMINE; ASACOL	5541170	JUL 30, 2013	U141		
		5541171	JUL 30, 2013	U141		
019618 001	MESALAMINE; ROWASA	4657900	APR 14, 2004			
		RE33239	MAY 12, 2004			
019884 001	MESNA; MESNEX	5696172	OCT 06, 2013			
020855 001	MESNA; MESNEX	5252341	JUL 16, 2011		NDF	MAR 21, 2005
		5262169	JUL 16, 2011			
013217 001	METAXALONE; SKELAXIN	6407128	DEC 03, 2021	U189		
013217 003	METAXALONE; SKELAXIN	6407128	DEC 03, 2021	U189		
021410 001	METFORMIN HYDROCHLORIDE; AVANDAMET	5002953	AUG 30, 2008	U493	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
021410 002	METFORMIN HYDROCHLORIDE; AVANDAMET	6166042	JUN 19, 2016	U493	NCE	MAY 25, 2004
		5002953	AUG 30, 2008	U493		
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
021410 003	METFORMIN HYDROCHLORIDE; AVANDAMET	6166042	JUN 19, 2016	U493	NCE	MAY 25, 2004
		5002953	AUG 30, 2008	U493		
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
021410 004	METFORMIN HYDROCHLORIDE; AVANDAMET	6166042	JUN 19, 2016	U493	NCE	MAY 25, 2004
021410 005	METFORMIN HYDROCHLORIDE; AVANDAMET				NCE	MAY 25, 2004
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED I-320 M-6 W W NDF	JUN 15, 2004 DEC 15, 2003 APR 19, 2004 DEC 15, 2003 JUN 15, 2004 OCT 13, 2003
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018			
		6660300	MAR 19, 2018	U542		
021202 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018		NDF	OCT 13, 2003
		6660300	MAR 19, 2018	U542		
020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009			
		5036102	JUL 30, 2008		U273	
		4999375	MAR 12, 2008			
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003		U372	
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003		U372	
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003		U372	
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4612008	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003		U372	
		5082668	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021259 002	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021259 003	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019		U472	
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019		U472	
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	NOV 01, 2019		U472	
019786 003	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019786 004	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007		U107	
		5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007		U107	
		5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745 5001161 5081154 4927640	SEP 18, 2007 MAR 19, 2008 MAR 19, 2008 MAY 22, 2007	U107	I-194	FEB 05, 2004
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745 5001161 5081154 4927640	SEP 18, 2007 MAR 19, 2008 MAR 19, 2008 MAY 22, 2007	U107 U107 U107	NS I-194	FEB 05, 2004 FEB 05, 2004
019737 001	METRONIDAZOLE;METROGEL	4837378	JUN 06, 2006			
020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5536743 4837378 5840744	JUL 16, 2013 JUN 06, 2006 JAN 15, 2008	U137		
020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014			
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATION PACK	6153635 5514698	NOV 28, 2020 MAR 21, 2014			
019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 003	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
020687 001	MIFEPRISTONE;MIFEPREX	4626531	OCT 12, 2004		NCE	SEP 28, 2005
020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
021348 001	MIGLUSTAT;ZAVESCA	5472969 5525616	MAY 13, 2013 JUN 11, 2013		NCE	JUL 31, 2008
020415 001	MIRTAZAPINE;REMERON				ODE	JUL 31, 2010
020415 002	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
020415 003	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4820738 4617319	APR 11, 2006 JUN 13, 2005	U98 U390	ODE I-324 ODE	NOV 13, 2003 OCT 13, 2003 OCT 13, 2007
020098 001	MIVACURIUM CHLORIDE;MIVACRON	4761418	JAN 22, 2006			
020098 002	MIVACURIUM CHLORIDE;MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006			
020717 001	MODAFINIL;PROVIGIL	4927855 RE37516	MAY 22, 2007 OCT 06, 2014	U255 U255	ODE NCE	DEC 24, 2005 DEC 24, 2003
020717 002	MODAFINIL;PROVIGIL	4927855 RE37516	MAY 22, 2007 OCT 06, 2014	U255 U255	ODE NCE	DEC 24, 2005 DEC 24, 2003
076204 001	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
020312 001	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020312 002	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699 6127353 5837699*PED 6127353*PED	JAN 27, 2014 OCT 03, 2017 JUL 27, 2014 APR 03, 2018	U249 U249	I-360 PED	JUL 17, 2005 JAN 17, 2006
019625 001	MOMETASONE FUROATE;ELOCON	4808610 4808610*PED	OCT 02, 2006 APR 02, 2007			
019796 001	MOMETASONE FUROATE;ELOCON	4775529 4775529*PED	MAY 21, 2007 NOV 21, 2007			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473 5565473*PED	FEB 03, 2012 AUG 03, 2012	U228 U228	PED I-378	AUG 20, 2003 DEC 31, 2005

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U228	PED	AUG 20, 2003
		5565473*PED	AUG 03, 2012	U228	I-378	DEC 31, 2005
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U228	PED	SEP 03, 2003
		5565473*PED	AUG 03, 2012	U228	PED	AUG 20, 2003
					PED	SEP 03, 2003
					I-378	DEC 31, 2005
021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012		NDF	JUL 26, 2005
		5565473*PED	AUG 03, 2012		PED	JAN 26, 2006
					PED	AUG 20, 2003
					I-378	DEC 31, 2005
021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
020616 001	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
020616 002	MORPHINE SULFATE;KADIAN	5378474	MAR 23, 2010			
		5202128	APR 13, 2010			
020616 003	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U298	I-329	APR 27, 2004
		5849752	DEC 05, 2016	U298	I-385	FEB 28, 2006
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHLORIDE 0.8%	4990517	JUN 30, 2009	U298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U298	NDF	NOV 30, 2004
		5849752	DEC 05, 2016	U298	I-329	APR 27, 2004
					I-385	FEB 28, 2006
021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	4990517	JUN 30, 2009		NDF	APR 15, 2006
		5607942	MAR 04, 2014		PED	OCT 15, 2006
		5849752	DEC 05, 2016		NCE	DEC 10, 2004
		4990517*PED	DEC 30, 2009		PED	JUN 10, 2004
		5607942*PED	SEP 04, 2014			
		5849752*PED	JUN 05, 2017			
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U232		
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U232		
021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012		I-411	OCT 20, 2006
		5488150	JAN 30, 2013			
		6559188	SEP 17, 2019			
021204 002	NATEGLINIDE;STARLIX	6641841	NOV 14, 2017	DP U214		
		RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012		I-411	OCT 20, 2006
		5488150	JAN 30, 2013			
		6559188	SEP 17, 2019			
		6641841	NOV 14, 2017	DP U214		
021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U304		
		4760072	JUL 26, 2005			
019660 001	NEDOCROMIL SODIUM;TILADE	4474787	OCT 02, 2006			
		4760072	JUL 26, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5952343*PED	APR 07, 2014	U257		
		5484926*PED	APR 07, 2014			
		6162812*PED	APR 07, 2014	U248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5484926*PED	APR 07, 2014			
		5952343*PED	APR 07, 2014	U257		
		6162812*PED	APR 07, 2014	U248		
021503 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		5952343	OCT 07, 2013	U257		
		5952343*PED	APR 07, 2014	U257		
		6162812	OCT 07, 2013	U248		
		6162812*PED	APR 07, 2014	U248		
020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U167		
020933 001	NEVIRAPINE;VIRAMUNE	5366972*PED	MAY 22, 2012			
		5366972	NOV 22, 2011			
020381 001	NIACIN;NIASPAN	5366972*PED	MAY 22, 2012			
		6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK	6080428	MAY 27, 2017	U331		
		6406715	OCT 31, 2017	U450		
		6129930	SEP 20, 2013	U354		
019734 001	NICARDIPINE HYDROCHLORIDE;CARDENE	4880823	NOV 14, 2006			
		5164405	NOV 17, 2009			
020005 001	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 002	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 003	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010		NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010		NDF	OCT 31, 2005
020076 001	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020076 002	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		
020076 003	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020165 004	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		6165497	JUN 14, 2008	U388		
		5633008	JUN 14, 2008	U389		
020165 005	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U389		
		6165497	JUN 14, 2008	U388		
020165 006	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U389		
		6165497	JUN 14, 2008	U388		
020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
		5501236	JUN 08, 2010			
020536 001	NICOTINE;NICOTROL	6098632	JUN 08, 2010			
		5400808	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	4917120	APR 17, 2007			
		4800903	JAN 31, 2006			
		4793366	DEC 27, 2005			
		5167242	JUN 08, 2010			
		5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
		4946853	AUG 07, 2007	U56		
		4946853	AUG 07, 2007	U56		
019983 001	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
019983 002	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
019983 003	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019983 004	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
020198 001	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 002	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 003	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
019684 001	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 002	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 003	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
020356 001	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 002	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 003	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 004	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
021498 001	NITAZOXANIDE;ALINIA	5387598	FEB 07, 2012	U524	NCE	NOV 22, 2007
		5578621	SEP 08, 2014	U525	ODE	NOV 22, 2009
		5965590	JUL 03, 2017	U523		
		5968961	MAY 07, 2017			
		6020353	SEP 08, 2014			
		6117894	MAY 07, 2017			
021232 001	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
021232 002	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
021232 003	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U297	ODE	DEC 23, 2006
		5873359	JAN 23, 2013	U297	NCE	DEC 23, 2004
020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U297	ODE	DEC 23, 2006
		5873359	JAN 23, 2013	U297	NCE	DEC 23, 2004
020064 001	NITROFURANTOIN;MACROBID	4772473	JUN 16, 2006			
		4798725	JUN 16, 2006			
020145 001	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 002	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 003	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 004	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 005	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 006	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021134 001	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
021134 002	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
021134 003	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
019757 001	NORFLOXACIN;CHIBROXIN	4551456	NOV 14, 2003	U57		
019384 002	NORFLOXACIN;NOROXIN	4639458	JAN 22, 2005			
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
		6395292	JAN 30, 2017			
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
019735 001	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U407	D-84	SEP 30, 2006
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		PED	NOV 22, 2003
		4551456	NOV 14, 2003	U80		
		4382892*PED	MAR 02, 2004			
		4551456*PED	MAY 14, 2004	U80		
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 002	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 003	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 004	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	5616599	APR 01, 2014	U500		
021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U500	NCE	APR 25, 2007
021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U500	NCE	APR 25, 2007



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021286 004	OLMESARTAN MEDOXOMIL; BENICAR				NCE	APR 25, 2007
020688 001	OLOPATADINE HYDROCHLORIDE; PATANOL	5641805	JUN 06, 2015	U184		
		4871865	OCT 03, 2006			
		4923892	MAY 08, 2007	U174		
		5116863	DEC 18, 2010			
019715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	JUL 31, 2004	U58		
021229 001	OMEPRAZOLE MAGNESIUM; PRILOSEC OTC	4738974	APR 19, 2005		RTO	JUN 20, 2006
		5900424	MAY 04, 2016			
		4786505	APR 20, 2007			
		4853230	APR 20, 2007			
		5690960	NOV 25, 2014			
		5817338	OCT 06, 2015			
		5753265	JUN 07, 2015			
		6403616	NOV 15, 2019			
		6428810	NOV 03, 2019			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
019810 001	OMEPRAZOLE; PRILOSEC	4786505	APR 20, 2007	U108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
019810 002	OMEPRAZOLE; PRILOSEC	4786505	APR 20, 2007	U108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
019810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U108	M-19	JUL 12, 2005
		4786505	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
020103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
020103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658	SEP 06, 2011			
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
020103 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	FEB 16, 2005	U44		
		5344658	SEP 06, 2011			
		4753789	JUN 24, 2006	U44		
020403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 25, 2005			
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	FEB 16, 2005	U44		
		5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE FREE	4695578	JAN 25, 2005	U183		
		5578628	FEB 16, 2005	U44		
		4695578	JAN 25, 2005			
020781 001	ONDANSETRON; ZOFRAN ODT	4753789	JUN 24, 2006	U44		
		5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
020781 002	ONDANSETRON; ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
		4598089	JUN 18, 2009			
020766 001	ORLISTAT; XENICAL	6004996	JAN 06, 2018		NCE	APR 23, 2004
		4598089*PED	DEC 18, 2009		PED	OCT 23, 2004
		6004996*PED	JUL 06, 2018		M-29	DEC 12, 2006
		5763483	DEC 27, 2016		PED	JUN 12, 2007
		5866601	FEB 02, 2016		NCE	OCT 27, 2004
		5952375	FEB 02, 2016		I-317	NOV 17, 2003
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483	DEC 27, 2016			
		5866601	FEB 02, 2016			
		5952375	FEB 02, 2016	U376		
		5763483	DEC 27, 2016		I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5952375	FEB 02, 2016		NCE	OCT 27, 2004
		5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
021492 001	OXALIPLATIN; ELOXATIN	5290961	JAN 12, 2013			
		5420319	APR 07, 2013			
		5338874	APR 07, 2013			
021492 002	OXALIPLATIN; ELOXATIN	5290961	JAN 12, 2013			
		5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
020776 001	OXAPROZIN POTASSIUM; DAYPRO ALTA	6030643	MAY 16, 2017	U497		
		4620974	NOV 04, 2003		NE	OCT 17, 2005
015539 002	OXAZEPAM; SERAX					

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
015539 004	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 006	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
017577 001	OXYBUTYNIN CHLORIDE;DITROPAN				M-28	APR 15, 2006
					PED	OCT 15, 2006
018211 001	OXYBUTYNIN CHLORIDE;DITROPAN				M-28	APR 15, 2006
					PED	OCT 15, 2006
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NPP	APR 15, 2006
		5674895	MAY 22, 2015		PED	OCT 15, 2006
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NPP	APR 15, 2006
		5674895	MAY 22, 2015		PED	OCT 15, 2006
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NPP	APR 15, 2006
		4612008	SEP 16, 2003		PED	OCT 15, 2006
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021351 002	OXYBUTYNIN; OXYTROL	6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
		5164190	DEC 11, 2010		NDF	FEB 26, 2006
		5601839	APR 26, 2015			
		5834010	APR 26, 2015			
020553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		4861598	AUG 29, 2006			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
020553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5656295	OCT 26, 2007	U443		
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		4861598	AUG 29, 2006			
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
		4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
020262 001	PALONOSETRON HYDROCHLORIDE; ALOXI	5656295	OCT 26, 2007	U443		
		5202333	APR 13, 2010	U528	ODE	AUG 04, 2004
		4711880	JUL 29, 2005		NCE	JUL 25, 2008
		4711880	JUL 29, 2005		D-68	AUG 20, 2004
		4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 003	PAMIDRONATE DISODIUM; AREZIA	4711880	JUL 29, 2005			
		4711880	JUL 29, 2005			
		4711880	JUL 29, 2005			
		4711880	JUL 29, 2005			
		4711880	JUL 29, 2005			
020036 004	PAMIDRONATE DISODIUM; AREZIA	4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
020987 001	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
020987 002	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV	4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
020819 001	PARICALCITOL; ZEMPLAR	4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
		5997903	DEC 07, 2016			
		4758579	JUL 19, 2010			
020819 001	PARICALCITOL; ZEMPLAR	5246925	APR 17, 2012	U314		
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
		6361758	APR 08, 2018			
		5246925*PED	OCT 17, 2012			
020819 001	PARICALCITOL; ZEMPLAR	5587497*PED	JUN 24, 2014			
		6136799*PED	OCT 08, 2019			
020819 001	PARICALCITOL; ZEMPLAR	5246925	APR 17, 2012			
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
		6361758	APR 08, 2018			
		5246925*PED	OCT 17, 2012			
020819 001	PARICALCITOL; ZEMPLAR	5587497*PED	JUN 24, 2014			
		6136799*PED	OCT 08, 2019			

DP

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6361758*PED	OCT 08, 2018			
075356 001	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 002	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 003	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 004	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES		
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	5872132*PED	NOV 19, 2015					
		5900423*PED	NOV 19, 2015					
		6080759*PED	NOV 19, 2015					
		6113944*PED	JUN 14, 2015					
		6121291*PED	SEP 17, 2017	U286				
		6121291*PED	SEP 17, 2017	U431				
		6133289*PED	NOV 19, 2015	U358				
		6172233*PED	JUL 15, 2018					
		6080759	MAY 19, 2015					
		4721723	DEC 29, 2006		I-326	APR 13, 2004		
		5872132	MAY 19, 2015		I-345	DEC 14, 2004		
		5900423	MAY 19, 2015		PED	OCT 13, 2004		
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005		
		6080759	MAY 19, 2015					
		6113944	DEC 14, 2014					
		6133289	MAY 15, 2015	U358				
		6121291	MAR 17, 2017	U286				
		6121291	MAR 17, 2017	U431				
		6172233	JAN 15, 2018					
		4721723*PED	JUN 29, 2007	U12				
		5789449*PED	JUL 06, 2009	U285				
		5872132*PED	NOV 19, 2015					
		5900423*PED	NOV 19, 2015					
6080759*PED	NOV 19, 2015							
6113944*PED	JUN 14, 2015							
6121291*PED	SEP 17, 2017	U286						
6121291*PED	SEP 17, 2017	U431						
6133289*PED	NOV 19, 2015	U358						
6172233*PED	JUL 15, 2018							
020031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004		
		5872132	MAY 19, 2015		I-345	DEC 14, 2004		
		5900423	MAY 19, 2015		PED	OCT 13, 2004		
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005		
		6080759	MAY 19, 2015					
		6113944	DEC 14, 2014					
		6121291	MAR 17, 2017	U286				
		6133289	MAY 15, 2015	U358				
		6172233	JAN 15, 2018					
		6121291	MAR 17, 2017	U431				
		4721723*PED	JUN 29, 2007	U12				
		5789449*PED	JUL 06, 2009	U285				
		5872132*PED	NOV 19, 2015					
		5900423*PED	NOV 19, 2015					
		6080759*PED	NOV 19, 2015					
		6113944*PED	JUN 14, 2015					
		6121291*PED	SEP 17, 2017	U286				
		6121291*PED	SEP 17, 2017	U431				
		6133289*PED	NOV 19, 2015	U358				
		6172233*PED	JUL 15, 2018					
		020710 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006		I-345	DEC 14, 2004
				5811436	SEP 22, 2015		I-326	APR 13, 2004
				5872132	MAY 19, 2015		PED	JUN 14, 2005
5900423	MAY 19, 2015				PED	OCT 13, 2004		
5789449	JAN 06, 2009			U285				
6080759	MAY 19, 2015							
6121291	MAR 17, 2017			U286				

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020885 001	PAROXETINE HYDROCHLORIDE; PAXIL	6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
5872132*PED	NOV 19, 2015					
5900423*PED	NOV 19, 2015					
6063927*PED	OCT 23, 2019					
6080759*PED	NOV 19, 2015					
6121291*PED	SEP 17, 2017	U286				
6121291*PED	SEP 17, 2017	U431				
6133289*PED	NOV 19, 2015	U358				
6172233*PED	JUL 15, 2018					
020885 002	PAROXETINE HYDROCHLORIDE; PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U286		
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U286		
		5872132*PED	NOV 19, 2015			
5900423*PED	NOV 19, 2015					



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6133289*PED	NOV 19, 2015	U286		
		6172233*PED	JUL 15, 2018			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
		5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009		U286	
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017		U286	
		6133289	MAY 19, 2015		U286	
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009		U286	
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
6121291*PED	SEP 17, 2017		U286			
6133289*PED	NOV 19, 2015		U286			
6172233*PED	JUL 15, 2018					
6548084	JUL 19, 2016					
6548084*PED	JAN 19, 2017					
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		5789449	JAN 06, 2009		U286	
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017		U286	
		6133289	MAY 19, 2015		U286	
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009		U286	
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017		U286	
		6133289*PED	NOV 19, 2015		U286	
		6172233*PED	JUL 15, 2018			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
		021299 001	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	
5874447	JUN 10, 2017				U518	
5874447	JUN 10, 2017				U46	
5874447	JUN 10, 2017					

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021299 002	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021299 003	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021299 004	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021106 001	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
		6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
021106 002	PEGVISOMANT;SOMAVERT	5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
		6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
021106 003	PEGVISOMANT;SOMAVERT	5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
		6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U184	PED	MAR 24, 2005
		5034230*PED	JUN 23, 2009	U184	NCE	SEP 24, 2004
		5075445	SEP 24, 2010		NPP	OCT 10, 2006
020629 001	PENCICLOVIR SODIUM;DENA VIR	6469015	OCT 22, 2019	U501		
		6573378	SEP 24, 2010			
		6579981	JUN 17, 2020	U501		
020193 001	PENTOSAN POLYSULFATE SODIUM;ELMIRON	5180715	JAN 19, 2010	U159	ODE	SEP 26, 2003
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE RED	5607979	MAY 30, 2015		NCE	FEB 17, 2005
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
019385 001	PERGOLIDE MESYLATE;PERMAX	5769080	JUL 20, 2010			
		4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 002	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 003	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
020184 001	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
020184 002	PERINDOPRIL ERBUMINE;ACEON	5162362	NOV 10, 2009	DS DP U531		
		4508729	AUG 21, 2006			
		5162362	NOV 10, 2009	DS DP U531		
020184 003	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
		5162362	NOV 10, 2009	DS DP U531		
020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
		5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
		6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6423722*PED	DEC 26, 2018			
		4687777	JAN 17, 2011		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
		6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
		4687777	JAN 17, 2011		NCE	JUL 15, 2004
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
		6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
		4687777	JAN 17, 2011		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
		4664107	MAY 12, 2004			
		4680399	JUL 14, 2004			
		5057616	OCT 15, 2008			
		5710183	JUL 14, 2015	U265		
		6048901	APR 20, 2019	U343		
020014 001	PIRBUTEROL ACETATE;MAXAIR					
020529 001	PODOFILOX;CONDYLOX					
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX					
020744 001	PORACTANT ALFA;CUROSURF				NCE	NOV 18, 2004
020451 001	PORFIMER SODIUM;PHOTOFRIN	4866168	MAR 10, 2004		I-391	AUG 01, 2006
		5028621	MAR 10, 2004		ODE	AUG 01, 2010
		5438071	AUG 01, 2012			
		4649151	MAR 10, 2004			
		4932934	JUN 12, 2007	U128		
		5145863	DEC 15, 2009	U129		
019439 002	POTASSIUM CHLORIDE;K-DUR 10	4863743	SEP 05, 2006	U99		
019439 001	POTASSIUM CHLORIDE;K-DUR 20	4863743	SEP 05, 2006	U99		
074726 003	POTASSIUM CHLORIDE;KLOR-CON M15				PC	DEC 24, 2003
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	DEC 09, 2003
		5030447	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5030447	JUL 09, 2008		PED	DEC 09, 2003
		5180589	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5030447	JUL 09, 2008		PED	DEC 09, 2003
		5180589	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		PED	DEC 09, 2003
		5180589*PED	JAN 09, 2009		PED	JUL 18, 2003
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		PED	AUG 10, 2003
					PED	JUL 18, 2003
					PED	JUL 18, 2003
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019775 001	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4765989	SEP 16, 2003			
019775 002	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	5082668	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE; CRINONE	4615697	OCT 07, 2003	U208		
		5543150	SEP 15, 2013	U209		
020701 002	PROGESTERONE; CRINONE	4615697	OCT 07, 2003	U208		
		5543150	SEP 15, 2013	U209		
021416 001	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 002	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 003	PROPAFENONE HYDROCHLORIDE; RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
019627 002	PROPOFOL; DIPRIVAN	5714520	MAR 22, 2015		I-322	FEB 20, 2004
		5714520*PED	SEP 22, 2015		PED	AUG 20, 2004
		5731355	MAR 22, 2015	U217		
		5731355*PED	SEP 22, 2015	U217		
		5731356	MAR 22, 2015	U218		
		5731356*PED	SEP 22, 2015	U218		
		5908869	MAR 22, 2015	U270		
		5908869*PED	SEP 22, 2015	U270		
019536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
021438 001	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
021438 002	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
020021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC 24 PSEUDOEPHEDRINE HCL	4801461	MAR 14, 2006			
020639 001	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011			
020639 002	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011			
020639 003	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011			
020639 004	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011			
020639 005	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011			
019885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
020973 001	RABEPRAZOLE SODIUM; ACIPHEX	5035899	APR 04, 2009	U385	NCE	AUG 19, 2004
		5045552	MAY 08, 2013	U385	I-346	FEB 12, 2005

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	MAY 08, 2013	U385	NCE	AUG 19, 2004
		5035899	APR 04, 2009	U385	I-346	FEB 12, 2005
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5393763	JUL 28, 2012	U114	I-371	NOV 08, 2005
		5457117	JUL 28, 2012	U114		
		5478847	MAR 02, 2014	U114		
		5811120	MAR 02, 2014			
		5972383	MAR 02, 2014	U287		
		6458811	MAR 10, 2017			
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 002	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
		4587258	JAN 27, 2005		I-310	OCT 04, 2003
019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
		5403856	APR 04, 2012	U71		
019901 004	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
019901 004	RAMIPRIL;ALTACE	5403856	APR 04, 2012	U71		
		5061722	OCT 19, 2008		I-310	OCT 04, 2003
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	4587258	JAN 27, 2005			
		5403856	APR 04, 2012	U71		
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U186		
		5008256	JUL 17, 2009			
		5256684	OCT 26, 2010	U199		
		5403830	APR 04, 2012	U200		
		5407688	APR 04, 2012	U201		
		5601848	FEB 11, 2014	U202		
		5456925	OCT 10, 2012			
		4585790	MAY 11, 2004			
		4585790*PED	NOV 11, 2004			
		4585790	MAY 11, 2004			
019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
		4585790	MAY 11, 2004			
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790*PED	NOV 11, 2004			
		4585790	MAY 11, 2004			
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5068249	NOV 26, 2008			
		5068249*PED	MAY 26, 2009			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4585790*PED	NOV 11, 2004			
		5028432	FEB 22, 2010			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432*PED	AUG 22, 2010			
		5102665	JUN 23, 2009			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5102665*PED	DEC 23, 2009			
		5102665	JUN 23, 2009			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	5102665*PED	DEC 23, 2009			
		5028432	FEB 22, 2010			
020984 001	RAPACURONIUM BROMIDE;RAPLON	5028432*PED	AUG 22, 2010			
		4880636	MAY 13, 2008			
020984 002	RAPACURONIUM BROMIDE;RAPLON	4880636*PED	NOV 13, 2008			
		5418226	APR 14, 2013		NCE	AUG 18, 2004
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5418226	APR 14, 2013		NCE	AUG 18, 2004
		5019583*PED	AUG 15, 2009			
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700	AUG 30, 2013	U156		
		5019583	FEB 15, 2009			
		5466700*PED	MAR 01, 2014	U156		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009			
		5466700	AUG 30, 2013	U156		
		5019583*PED	AUG 15, 2009			
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700*PED	MAR 01, 2014			
		5019583	FEB 15, 2009			
		5466700	AUG 30, 2013	U156		
020741 001	REPAGLINIDE; PRANDIN	5019583*PED	AUG 15, 2009	U156		
		5466700*PED	MAR 01, 2014			
		5312924	SEP 05, 2006		I-367	OCT 21, 2005
020741 002	REPAGLINIDE; PRANDIN	6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
		5312924	SEP 05, 2006	U214	I-367	OCT 21, 2005
020741 003	REPAGLINIDE; PRANDIN	6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
		5312924	SEP 05, 2006	U214	I-367	OCT 21, 2005
021511 001	RIBAVIRIN; COPEGUS	6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
		5767097	JAN 23, 2016	U235	NP	DEC 03, 2005
020903 001	RIBAVIRIN; REBETOL	5914128	DEC 22, 2017		M-26	MAR 06, 2005
		6051252	DEC 22, 2017		ODE	JUL 29, 2010
		6063772	JAN 23, 2016	U375	PED	JAN 29, 2011
020903 002	RIBAVIRIN; REBETOL	6172046	SEP 21, 2017	U377		
		5767097*PED	JUL 23, 2016	U235		
		5914128*PED	JUN 22, 2018			
020903 002	RIBAVIRIN; REBETOL	6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U375		
		6172046*PED	MAR 21, 2018	U377		
020903 002	RIBAVIRIN; REBETOL	6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018		M-26	MAR 06, 2005
		5767097	JAN 23, 2016	U235	ODE	JUL 29, 2010
020903 002	RIBAVIRIN; REBETOL	5767097*PED	JUL 23, 2016	U235	PED	JAN 29, 2011
		5914128	DEC 22, 2017			
		5914128*PED	JUN 22, 2018			
020903 002	RIBAVIRIN; REBETOL	6051252	DEC 22, 2017			
		6051252*PED	JUN 22, 2018			
		6063772	JAN 23, 2016	U375		
020903 002	RIBAVIRIN; REBETOL	6063772*PED	JUL 23, 2016	U375		
		6172046	SEP 21, 2017	U377		
		6172046*PED	MAR 21, 2018	U377		
020903 002	RIBAVIRIN; REBETOL	6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			
		6177074	NOV 01, 2016	U454		
020903 002	RIBAVIRIN; REBETOL	6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
020903 002	RIBAVIRIN; REBETOL	6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
020903 002	RIBAVIRIN; REBETOL	6524570*PED	MAY 01, 2017	U499		
		6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018		M-26	MAR 06, 2005
020903 002	RIBAVIRIN; REBETOL	5767097	JAN 23, 2016	U235	ODE	JUL 29, 2010
		5767097*PED	JUL 23, 2016	U235	PED	JAN 29, 2011
		5914128	DEC 22, 2017			
020903 002	RIBAVIRIN; REBETOL	5914128*PED	JUN 22, 2018			
		6051252	DEC 22, 2017			
		6051252*PED	JUN 22, 2018			
020903 002	RIBAVIRIN; REBETOL	6063772	JAN 23, 2016	U375		
		6063772*PED	JUL 23, 2016	U375		
		6172046	SEP 21, 2017	U377		
020903 002	RIBAVIRIN; REBETOL	6172046*PED	MAR 21, 2018	U377		
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES			
021546 001	RIBAVIRIN;REBETOL	6472373	SEP 21, 2017	U521	NDF	JUL 29, 2006			
		6472373*PED	MAR 21, 2018	U521	PED	JAN 29, 2007			
		6461605	NOV 01, 2016	U521	ODE	JUL 29, 2010			
		6461605*PED	MAY 01, 2017	U521	PED	JAN 29, 2011			
		6172046	SEP 21, 2017	U521					
		6172046*PED	MAR 21, 2018	U521					
		6063772	JAN 23, 2016	U521					
		6063772*PED	JUL 23, 2016	U521					
		5767097	JAN 23, 2016	U521					
		5767097*PED	JUL 23, 2016	U521					
018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U400					
021024 001	RIFAPENTINE; PRIFTIN				ODE	JUN 22, 2005			
020599 001	RILUZOLE; RILUTEK	5527814	JUN 18, 2013						
020474 001	RIMEXOLONE; VEXOL	4686214	JUL 22, 2008	U100					
020835 001	RISEDRONATE SODIUM; ACTONEL	5583122	DEC 10, 2013	U222					
		6096342	NOV 22, 2011						
		6165513	JUN 10, 2018						
		5583122	DEC 10, 2013	U222					
		6096342	NOV 22, 2011						
020835 002	RISEDRONATE SODIUM; ACTONEL	6165513	JUN 10, 2018						
		5583122	DEC 10, 2013	U222					
		6096342	NOV 22, 2011						
		6165513	JUN 10, 2018						
		5994329	JUL 17, 2018	U353	D-73	MAY 17, 2005			
020835 003	RISEDRONATE SODIUM; ACTONEL	6015801	JUL 17, 2018	U353	D-74	MAY 17, 2005			
		5583122	DEC 10, 2013	U222					
		6096342	NOV 22, 2011						
		6165513	JUN 10, 2018						
		4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005			
020272 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 002	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 003	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 004	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 005	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 007	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020272 008	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
020588 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U90	I-412	DEC 04, 2006			
					I-413	DEC 04, 2006			
					M-15	MAR 03, 2005			
					I-412	DEC 04, 2006			
021444 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U516	M-15	MAR 03, 2005			
					5648093	JUL 15, 2014	I-412	DEC 04, 2006	
					6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
					5453425	JUL 11, 2014			



PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021444 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U516	M-15	MAR 03, 2005
		5648093	JUL 15, 2014		I-412	DEC 04, 2006
		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
021444 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007		M-15	MAR 03, 2005
		5648093	JUL 15, 2014		I-412	DEC 04, 2006
		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
021346 001	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
021346 002	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
021346 003	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020659 001	RITONAVIR;NORVIR	6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
		5635523	JUN 03, 2014	U190		
		5484801	JAN 28, 2014			
		5541206	JUL 30, 2013	U140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U190		
020680 001	RITONAVIR;NORVIR	6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			
		5635523	JUN 03, 2014	U190		
		5541206	JUL 30, 2013	U140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U190		
020945 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U347		
		5541206	JUL 30, 2013	U348		
		5635523	JUN 03, 2014	U347		
		6232333	NOV 07, 2017			
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
020823 003	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U322		
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
020823 004	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U322		
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
020823 005	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U322		
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
020823 006	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U322		
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
021025 001	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U322		
		4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014	U240		
		5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014	U240		
		5457895	OCT 01, 2013			
020214 002	ROCURONIUM BROMIDE;ZEMURON	4894369	APR 13, 2008			
		4894369	APR 13, 2008			
020214 001	ROCURONIUM BROMIDE;ZEMURON (P/F)	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
021042 001	ROFECOXIB;VIOXX	6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013		NCE	MAY 20, 2004
		5474995	JUN 24, 2013	U266	I-353	APR 11, 2005
		5691374	MAY 18, 2015		M-27	AUG 06, 2006
		6063811	MAY 06, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4824860	MAY 19, 2008	U212		
		4452808	DEC 07, 2007			
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		D-64	NOV 02, 2003
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004			
		4695576	SEP 22, 2004		D-64	NOV 02, 2003
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010			
		4695576	SEP 22, 2004		D-64	NOV 02, 2003
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010			
		4695576	SEP 22, 2004		D-64	NOV 02, 2003
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
		5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
		5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U420		
		5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
021366 002	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 003	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 004	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 005	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U503		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020772 001	SACROSIDASE; SUCRAID				ODE	APR 09, 2005
020236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008			
		5225445	FEB 12, 2008	U182		
		5126375	FEB 12, 2008			
020692 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		I-348	MAR 22, 2005
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM; QUADRAMET	4898724	FEB 06, 2007	U187		
020628 001	SAQUINAVIR MESYLATE; INVIRASE	5196438	NOV 19, 2010			
020828 001	SAQUINAVIR; FORTOVASE	5196438	NOV 19, 2010			
		6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021136 001	SECRETIN; SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
					I-408	NOV 01, 2005
					NP	APR 04, 2005
					ODE	APR 04, 2009
021209 001	SECRETIN; SECREFLO					
019863 001	SERMORELIN ACETATE; GEREF	4703035	DEC 28, 2004	U47		
020443 001	SERMORELIN ACETATE; GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
020443 002	SERMORELIN ACETATE; GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
021385 001	SERTACONAZOLE NITRATE; ERTACZO				NCE	DEC 10, 2008
019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4962128*PED	MAY 02, 2010	U152	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U12	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U12	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U12	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U286	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U286	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013		I-261	FEB 07, 2006
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
		5789449	JAN 06, 2009	U460		
020926 001	SEVELAMER HYDROCHLORIDE; RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
021179 001	SEVELAMER HYDROCHLORIDE; RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
021179 002	SEVELAMER HYDROCHLORIDE; RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
020478 001	SEVOFLURANE; ULTANE	5990176	JAN 27, 2017		M-17	MAR 30, 2004
		6074668	JAN 09, 2018		PED	SEP 30, 2004
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
		6288127	JAN 27, 2017			
		6288127*PED	JUL 27, 2017			
		6444859	JAN 27, 2017			
		6444859*PED	JUL 27, 2017			
		4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
020632 001	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	5436272	JUL 25, 2012	U439		
		4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
020632 002	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	5436272	JUL 25, 2012	U439		
		4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
020632 003	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	5436272	JUL 25, 2012	U439		
		4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
020895 001	SILDENAFIL CITRATE; VIAGRA	5436272	JUL 25, 2012	U439		
		5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
020895 002	SILDENAFIL CITRATE; VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
		5250534	MAR 27, 2012			
020895 003	SILDENAFIL CITRATE; VIAGRA	6469012	OCT 22, 2019	U155		
		5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
019766 001	SIMVASTATIN; ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019766 002	SIMVASTATIN; ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
019766 003	SIMVASTATIN; ZOCOR	RE36520*PED	NOV 26, 2009	U300		
		4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
019766 004	SIMVASTATIN; ZOCOR	RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
		4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
019766 005	SIMVASTATIN; ZOCOR	4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
		4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
021083 001	SIROLIMUS; RAPAMUNE	RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
		5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
021110 001	SIROLIMUS; RAPAMUNE	5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5536729	SEP 30, 2013			
		5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
021110 002	SIROLIMUS; RAPAMUNE	5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5989591	MAR 11, 2018			
		5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
020955 001	SODIUM FERRIC GLUCONATE COMPLEX; FERRLECIT	5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5989591	MAR 11, 2018			
		NCE			NCE	FEB 18, 2004
020231 001	SODIUM FLUORIDE; COLGATE TOTAL	5288480	JUL 16, 2008			
021196 001	SODIUM OXYBATE; XYREM	4894220	JAN 16, 2007	DP		
		5037635	JAN 16, 2007	DP		
		5156835	OCT 20, 2009	DP		
		5344641	MAR 09, 2010	DP		
		5538715	JAN 16, 2007	DP		
5776435	JAN 16, 2007	DP				
020572 001	SODIUM PHENYL BUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U136	ODE	JUL 17, 2009
		4457942	AUG 20, 2004	U136	NCE	JUL 17, 2007
020573 001	SODIUM PHENYL BUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U136		
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; VISICOL	5616346	MAY 18, 2013	U359	NP	SEP 21, 2003

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019107 001	SOMATREM; PROTROPIN	4658021	APR 14, 2004			
020280 006	SOMATROPIN RECOMBINANT; GENOTROPIN	4968299	JUN 28, 2008		ODE	OCT 31, 2004
		5633352	MAR 10, 2015		ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 007	SOMATROPIN RECOMBINANT; GENOTROPIN	4968299	JUN 28, 2008		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 005	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5435076	APR 16, 2013		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019640 001	SOMATROPIN RECOMBINANT; HUMATROPE				ODE	DEC 30, 2003
019640 004	SOMATROPIN RECOMBINANT; HUMATROPE				I-398	JUL 25, 2006
019640 005	SOMATROPIN RECOMBINANT; HUMATROPE				ODE	DEC 30, 2003
019640 006	SOMATROPIN RECOMBINANT; HUMATROPE				I-398	JUL 25, 2006
019640 007	SOMATROPIN RECOMBINANT; HUMATROPE				ODE	DEC 30, 2003
019721 001	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014		I-398	JUL 25, 2006
019721 002	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014			
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
019676 001	SOMATROPIN RECOMBINANT; NUTROPIN				ODE	OCT 29, 2004
019676 002	SOMATROPIN RECOMBINANT; NUTROPIN				ODE	OCT 29, 2004
020168 001	SOMATROPIN RECOMBINANT; NUTROPIN				ODE	DEC 30, 2003
020168 002	SOMATROPIN RECOMBINANT; NUTROPIN				ODE	DEC 30, 2003
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
020604 001	SOMATROPIN RECOMBINANT; SEROSTIM				ODE	AUG 23, 2003
020604 002	SOMATROPIN RECOMBINANT; SEROSTIM				ODE	AUG 23, 2003
020604 004	SOMATROPIN RECOMBINANT; SEROSTIM				ODE	AUG 23, 2003
021597 001	SOMATROPIN RECOMBINANT; ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 002	SOMATROPIN RECOMBINANT; ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 003	SOMATROPIN RECOMBINANT; ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 004	SOMATROPIN RECOMBINANT; ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
019865 001	SOTALOL HYDROCHLORIDE; BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE; BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				M-13	OCT 01, 2004
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	APR 01, 2005
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 006	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 007	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
020677 001	SPARFLOXACIN; ZAGAM	4795751	FEB 04, 2010	U160		
020240 001	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 002	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 003	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 004	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020412 001	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U94		
020412 002	STAVUDINE; ZERIT	4978655*PED	DEC 24, 2008	U94		
020412 003	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U94		
020412 004	STAVUDINE; ZERIT	4978655*PED	DEC 24, 2008	U94		
020412 005	STAVUDINE; ZERIT	4978655	JUN 24, 2008	U94		
020413 001	STAVUDINE; ZERIT	4978655*PED	DEC 24, 2008	U94		
021453 001	STAVUDINE; ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
021453 002	STAVUDINE; ZERIT XR	4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
021453 003	STAVUDINE; ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
021453 004	STAVUDINE; ZERIT XR	4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 004	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U444		
020132 005	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016	U72		
020132 006	SUMATRIPTAN SUCCINATE; IMITREX	6020001	MAR 02, 2012	U444		
020132 007	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
020132 008	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 009	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U444		
020132 010	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016	U72		
020132 011	SUMATRIPTAN SUCCINATE; IMITREX	6020001	MAR 02, 2012	U444		
020132 012	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
020132 013	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
020132 014	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U444		
020132 015	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016	U72		
020132 016	SUMATRIPTAN SUCCINATE; IMITREX	6020001	MAR 02, 2012	U444		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020626 001	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020626 002	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020626 003	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020070 001	TACRINE HYDROCHLORIDE; COGNEX	4631286	OCT 25, 2004	U97		
020070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	SEP 09, 2007			
		4631286	OCT 25, 2004	U97		
020070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	SEP 09, 2007			
		4631286	OCT 25, 2004	U97		
020070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	SEP 09, 2007			
		4631286	OCT 25, 2004	U97		
		4816456	SEP 09, 2007			
021368 001	TADALAFIL; CIALIS				NCE	NOV 21, 2008
021368 002	TADALAFIL; CIALIS				NCE	NOV 21, 2008
021368 003	TADALAFIL; CIALIS				NCE	NOV 21, 2008
020587 001	TALC; SCLEROSOL				ODE	DEC 24, 2004
017970 001	TAMOXIFEN CITRATE; NOLVADEX				M-20 PED	AUG 30, 2005 MAR 01, 2006
020579 001	TAMSULOSIN HYDROCHLORIDE; FLOMAX	4868216	SEP 19, 2006	U181		
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2009			
		4772475	FEB 27, 2006			
		5089509	JUN 13, 2011	U481		
021184 003	TAZAROTENE; AVAGE	5089509	JUN 13, 2011	U193	NP	SEP 30, 2005
020600 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U481		
		5914334	JUN 07, 2014	U517		
020600 002	TAZAROTENE; TAZORAC	6258830	JUN 07, 2014	U517		
		5089509	JUN 13, 2011	U193		
		5089509	JUN 13, 2011	U481		
		5914334	JUN 07, 2014	U517		
		6258830	JUN 07, 2014	U517		
021184 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U481	NDF	SEP 29, 2003
021184 002	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U481	NDF	SEP 29, 2003
					I-344	OCT 11, 2004
020887 001	TECHNETIUM TC-99M APCITIDE; ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
		5645815	JUL 08, 2014			
		5443815	AUG 22, 2012			
020256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE	5279811	NOV 23, 2008	U101		
		5431900	JUL 11, 2012	U336		
021012 001	TECHNETIUM TC-99M DEPREOTIDE; NEO TECT KIT				NCE	AUG 03, 2004
019829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4615876	OCT 07, 2003			
		4789736	DEC 06, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT;ULTRATAG	4755375	JUL 05, 2005	U51		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	4705849	NOV 10, 2004			
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008		I-396	FEB 28, 2006
021200 001	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U466	NCE	JUL 24, 2007
021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U466	NCE	JUL 24, 2007
020850 001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
020850 002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
020850 003	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
018163 003	TEMAZEPAM;RESTORIL	5030632	JUL 09, 2008	U70		
		5326758	JUL 09, 2008	U70		
		5211954	MAY 18, 2010			
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U248	NPP	AUG 15, 2006
		5935946	JUL 25, 2017	U248		
		4808716	APR 25, 2006	U248		
		6057305	MAY 02, 2017	U248		
		5922695	JUL 25, 2017	U248		
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095 5212176 5294615	APR 29, 2013 JUN 29, 2010 APR 29, 2013	U165 U3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095 5212176 5294615	APR 29, 2013 JUN 29, 2010 APR 29, 2013	U165 U3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176 5412095 5294615	JUN 29, 2010 APR 29, 2013 APR 29, 2013	U165 U3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176 5412095 5294615	JUN 29, 2010 APR 29, 2013 APR 29, 2013	U165 U3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176 5412095 5294615	JUN 29, 2010 APR 29, 2013 APR 29, 2013	U165 U3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176 5412095 5294615	JUN 29, 2010 APR 29, 2013 APR 29, 2013	U165 U3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U73		
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534 4680291	DEC 30, 2006 JUL 14, 2004	U73 U281		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534 6121314	DEC 30, 2006 MAY 18, 2012	U502		
020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291 4755534	JUL 14, 2004 DEC 30, 2006	U73 U73		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291 4755534 5681849	JUL 14, 2004 DEC 30, 2006 OCT 28, 2014	U73 U73		
020846 001	TERBINAFINE;LAMISIL	6121314 4755534 4680291	MAY 18, 2012 DEC 30, 2006 JUL 14, 2004	U504 U445 U445		
021318 001	TERIPARATIDE RECOMBINANT HUMAN;FORTEO				NP	NOV 26, 2005
020489 001	TESTOSTERONE;ANDRODERM	4863970 4983395 5152997 5164190 4849224 4855294	NOV 14, 2006 NOV 12, 2007 DEC 11, 2010 DEC 11, 2010 NOV 12, 2007 SEP 06, 2008	U490		
020489 002	TESTOSTERONE;ANDRODERM	4849224 4855294 4863970 4983395 5152997 5164190	NOV 12, 2007 SEP 06, 2008 NOV 14, 2006 NOV 12, 2007 DEC 11, 2010 DEC 11, 2010	U490		
021015 001	TESTOSTERONE;ANDROGEL	6503894	AUG 30, 2020	U490		
021543 001	TESTOSTERONE;STRIANT	4615697 6248358	OCT 07, 2003 AUG 23, 2019	U527	NP	JUN 19, 2006

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021454 001	TESTOSTERONE;TESTIM	5023252	JUN 11, 2008	U483	NP	OCT 31, 2005
019762 001	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4725439	FEB 16, 2005			
		4867982	FEB 16, 2005			
		5840327	AUG 15, 2016			
019762 002	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		5840327	AUG 15, 2016			
020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U440		
020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	NCE	JUL 16, 2003
		6315720	OCT 23, 2020	U442	ODE	JUL 16, 2005
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020785 002	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	ODE	JUL 16, 2005
		6315720	OCT 23, 2020	U442	NCE	JUL 16, 2003
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020785 003	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	ODE	JUL 16, 2005
		6315720	OCT 23, 2020	U442	NCE	JUL 16, 2003
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010		ODE	NOV 30, 2005
		5602006	FEB 11, 2014		NCE	NOV 30, 2003
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010			
		4980171	APR 06, 2009			
020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020439 001	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020439 002	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020484 001	TINZAPARIN SODIUM;INNOHEP					
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U230	NCE	JUL 14, 2005
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U230		
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
		5476875	DEC 19, 2012	U219		
020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
		5476875	DEC 19, 2012	U219		
020771 001	TOLTERODINE TARTRATE;DETROL	5382600	MAR 25, 2012			
		5559269	NOV 05, 2013	U318		
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
020771 002	TOLTERODINE TARTRATE;DETROL	5382600	MAR 25, 2012			
		5559269	NOV 05, 2013	U318		
		5382600*PED	SEP 25, 2012			
		5550269*PED	MAY 05, 2014			
021228 001	TOLTERODINE TARTRATE;DETROL LA	5382600	MAR 25, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U318	PED	JUN 22, 2004
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
		6630162	NOV 11, 2019	DP U544		
		6630162*PED	MAY 11, 2020			
021228 002	TOLTERODINE TARTRATE;DETROL LA	5382600	MAR 25, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U318	PED	JUN 22, 2004
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
		6630162	NOV 11, 2019	DP U544		
		6630162*PED	MAY 11, 2020			
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		ODE	AUG 28, 2008
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		ODE	AUG 28, 2008
020671 001	TOPOTECAN HYDROCHLORIDE;HYCANTIN	5004758	MAY 28, 2010		I-335	AUG 28, 2004
020497 001	TOREMIFENE CITRATE;FARESTON	5004758*PED	NOV 28, 2010			
020136 001	TORSEMIDE;DEMADEX	4696949	SEP 29, 2009	U196	ODE	MAY 29, 2004
020136 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 003	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 004	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	4861786	JUL 08, 2007			
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U435		
020528 001	TRANDOLAPRIL;MAVIK	6339105*PED	APR 12, 2020	U435		
020528 002	TRANDOLAPRIL;MAVIK	6339105	OCT 12, 2019	U435		
020528 003	TRANDOLAPRIL;MAVIK	6339105*PED	APR 12, 2020	U435		
020591 001	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
020591 002	TRANDOLAPRIL;TARKA	5744496	APR 28, 2015	U229		
020591 003	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
020591 004	TRANDOLAPRIL;TARKA	5744496	APR 28, 2015	U229		
021257 001	TRAVOPROST;TRAVATAN	4933361	JUN 12, 2007			
021272 001	TREPROSTINIL SODIUM;REMODULIN	5721244	FEB 24, 2015			
021272 002	TREPROSTINIL SODIUM;REMODULIN	6011062	DEC 22, 2014	U382	NCE	MAR 16, 2006
021272 003	TREPROSTINIL SODIUM;REMODULIN	5631287	DEC 22, 2014	U382	M-23	FEB 13, 2006
		5849792	DEC 22, 2014	U383		
		5889052	AUG 03, 2013	U383		
		6235781	JUN 15, 2019	U382		
		5153222	OCT 06, 2009	U455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
					NCE	MAY 21, 2007
					ODE	MAY 21, 2009
					NCE	MAY 21, 2007
					ODE	MAY 21, 2009

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U455	NCE ODE	MAY 21, 2007 MAY 21, 2009
020404 003	TRETINOIN;AVITA	4971800 5045317	NOV 20, 2007 SEP 03, 2008	U178 U179		
019963 001	TRETINOIN;RENOVA	4603146 RE36068	JUL 29, 2003 JUL 29, 2003	U131 U131		
021108 001	TRETINOIN;RENOVA	RE36068 4603146 6531141	JUL 29, 2003 JUL 29, 2003 MAR 07, 2020	U131 U131	NP	AUG 31, 2003
020475 001	TRETINOIN;RETIN-A MICRO	4690825 5955109	OCT 04, 2005 SEP 21, 2016	U134 U134		
020475 002	TRETINOIN;RETIN-A MICRO	4690825 5955109	OCT 04, 2005 SEP 21, 2016	U134 U134	NS	MAY 10, 2005
019798 001	TRIAMCINOLONE ACETONIDE;NASACORT	4767612	JAN 23, 2007	U85		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573 6143329	JUL 03, 2016 JUL 03, 2016	U295		
074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449 5962461	AUG 07, 2016 AUG 07, 2016			
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4694007 4376858 6017922	MAY 20, 2006 MAY 09, 2004 MAY 18, 2018	U91		
020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP NCE NCE	JUN 29, 2004 JUN 15, 2005 JUN 15, 2005
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5225205 5776885	JUL 20, 2010 JUL 07, 2015			
020719 001	TROGLITAZONE;PRELAY	4572912 5602133 5859037	NOV 09, 2008 SEP 15, 2013 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		
020719 002	TROGLITAZONE;PRELAY	4572912 5602133 5859037	NOV 09, 2008 SEP 15, 2013 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		
020719 003	TROGLITAZONE;PRELAY	5602133 4572912 5859037	SEP 15, 2013 NOV 09, 2008 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		
020720 001	TROGLITAZONE;REZULIN	5602133 4572912 5859037	SEP 15, 2013 NOV 09, 2008 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		
020720 002	TROGLITAZONE;REZULIN	5602133 4572912 5859037	SEP 15, 2013 NOV 09, 2008 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		
020720 003	TROGLITAZONE;REZULIN	5602133 4572912 5859037	SEP 15, 2013 NOV 09, 2008 NOV 13, 2017	U173 U251		
		6011049 6046202	NOV 13, 2017 SEP 15, 2013	U301 U317		



PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U282		
		5763454	JUN 15, 2015	U282		
		6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U282		
		5763454	JUN 15, 2015	U282		
		6187341	JAN 20, 2019			
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U333		
		5166178	NOV 24, 2009	U333		
		5212200	MAY 18, 2010	U333		
		5208256	MAY 21, 2011	U333		
		5221763	JUN 22, 2010			
020586 002	UREA, C-13;BREATHTEK UBT FOR H-PYLORI	4830010	OCT 27, 2009	U147		
020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	5140993	AUG 24, 2009	U148		
		4830010	OCT 27, 2009	U147		
020617 001	UREA, C-14;PYTEST	5140993	AUG 24, 2009	U148		
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U195		
021289 001	UROFOLLITROPIN;BRAVELLE	4830010	MAY 15, 2006	U195	NP	MAY 06, 2005
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U408		
		4725579	FEB 21, 2005	U408		
		4589402	JUL 26, 2004	U482		
		5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U408		
019415 005	UROFOLLITROPIN;FERTINEX	4725579	FEB 21, 2005	U408		
		4589402	JUL 26, 2004	U482		
		5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U408		
		4725579	FEB 21, 2005	U408		
		4589402	JUL 26, 2004	U482		
020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		ODE	DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009	U530	D-67	JUN 25, 2004
		5879706	JAN 19, 2016	U530	I-381	SEP 09, 2005
		6107302	JAN 19, 2016	U530	I-403	AUG 29, 2006
					I-389	APR 01, 2006
					D-67	JUN 25, 2004
					I-381	SEP 09, 2005
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	5879706	JAN 19, 2016	U530	D-67	JUN 25, 2004
		6107302	JAN 19, 2016	U530	I-381	SEP 09, 2005
		4957924	JUN 23, 2009	U530	I-403	AUG 29, 2006
					I-389	APR 01, 2006
					NCE	NOV 16, 2006
					NCE	NOV 16, 2006
021341 002	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U462	NCE	NOV 16, 2006
021341 003	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U462	NCE	NOV 16, 2006
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U384	NE	MAR 29, 2004
020593 001	VALPROATE SODIUM;DEPACON				I-406	SEP 12, 2006
					D-72	JAN 24, 2005
020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	ODE	SEP 25, 2005
		5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
		5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
021283 001	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U3		
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		

PRESCRIPTION AND OTC DRUG PRODUCT  
 PATENT AND EXCLUSIVITY DATA  
 See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021283 004	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		
021400 001	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 002	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 003	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 004	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U315		
		6096339	APR 04, 2017	U365		
		6146662	AUG 14, 2007	U366		
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U315		
		6096339	APR 04, 2017	U365		
		6146662	AUG 14, 2007	U366		

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019614 001	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 002	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 003	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012		I-336	AUG 22, 2004
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U357		
		5798349	AUG 25, 2015	U357		
		5756541	MAR 11, 2016	U357		
		4883790	JAN 20, 2007			
		5283255	JAN 20, 2007	U357		
014103 003	VINCRIStINE SULFATE;ONCOVIN	4619935	OCT 28, 2003			
021266 001	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DS DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021266 002	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DS DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021267 001	VORICONAZOLE;VFEND	5773443	JAN 25, 2011	DS DP U540	NCE	MAY 24, 2007
		5116844	AUG 11, 2009	DS DP U540	I-409	NOV 14, 2006
		5364938	NOV 15, 2011	DS		
		5567817	OCT 22, 2013	DS DP U540		
		6632803	JUN 02, 2018	DP		
		5376645	JAN 23, 2010	DP		
		5134127	JAN 23, 2010	DP		
020547 001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U189		
		5583152	SEP 26, 2010			
		4859692	SEP 26, 2010			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		5482963	JAN 09, 2013			
020547 003	ZAFIRLUKAST;ACCOLATE	6143775	DEC 11, 2011			
		4859692	SEP 26, 2010			
		5294636	DEC 11, 2011			
		5319097	DEC 11, 2011			
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U189		
		6143775	DEC 11, 2011			
020199 001	ZALCITABINE;HIVID	5028595	JUL 02, 2008	U65		
		4879277	NOV 07, 2006	U65		
020199 002	ZALCITABINE;HIVID	4879277	NOV 07, 2006	U65		
		5028595	JUL 02, 2008	U65		
020859 001	ZALEPLON;SONATA	4626538	JUN 06, 2008		NCE	AUG 13, 2004
					M-8	FEB 22, 2004

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020859 002	ZALEPLON; SONATA	4626538	JUN 06, 2008		NCE	AUG 13, 2004
021036 001	ZANAMIVIR; RELENZA	5360817	NOV 01, 2011		M-8	FEB 22, 2004
		5648379	JUL 15, 2014	U274	NCE	JUL 26, 2004
		6294572	DEC 15, 2014			
019655 001	ZIDOVUDINE; RETROVIR	4724232	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
019910 001	ZIDOVUDINE; RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
019951 001	ZIDOVUDINE; RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4837208	SEP 17, 2005			
020518 001	ZIDOVUDINE; RETROVIR	4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
020518 002	ZIDOVUDINE; RETROVIR	4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
020471 001	ZILEUTON; ZYFLO	4873259	DEC 10, 2010	U168		
020471 003	ZILEUTON; ZYFLO	4873259	DEC 10, 2010	U168		
020458 001	ZINC ACETATE; GALZIN				ODE	JAN 28, 2004
020458 002	ZINC ACETATE; GALZIN				ODE	JAN 28, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020919 001	ZIPRASIDONE MESYLATE; GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
		4831031	MAR 02, 2007		NDF	JUN 21, 2005
		6110918	MAR 26, 2017			
		6232304	APR 01, 2017			
021223 001	ZOLEDRONIC ACID; ZOMETA	4939130	NOV 13, 2007	U53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
					I-361	FEB 22, 2005
021223 002	ZOLEDRONIC ACID; ZOMETA	4777163	JUL 24, 2007		NCE	AUG 20, 2006
		4939130	NOV 13, 2007	U53	I-361	FEB 22, 2005
					ODE	AUG 20, 2008

PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY DATA  
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020768 001	ZOLMITRIPTAN; ZOMIG	5466699	NOV 14, 2012			
		5863935	NOV 14, 2012			
		5466699*PED	MAY 14, 2013			
020768 002	ZOLMITRIPTAN; ZOMIG	5863935*PED	MAY 14, 2013			
		5466699	NOV 14, 2012			
		5863935	NOV 14, 2012			
021450 004	ZOLMITRIPTAN; ZOMIG	5466699*PED	MAY 14, 2013			
		5466699	NOV 14, 2012	U436	NDF	SEP 26, 2006
		5466699*PED	MAY 14, 2013		PED	MAR 26, 2007
021231 001	ZOLMITRIPTAN; ZOMIG-ZMT	5466699	NOV 14, 2012		NDF	FEB 13, 2004
		5466699*PED	MAY 14, 2013		PED	AUG 13, 2004
		5466699	NOV 14, 2012		NDF	FEB 13, 2004
021231 002	ZOLMITRIPTAN; ZOMIG-ZMT	5466699*PED	MAY 14, 2013		PED	AUG 13, 2004
		4382938	OCT 21, 2006	U74		
		4382938	OCT 21, 2006	U74		
019908 001	ZOLPIDEM TARTRATE; AMBIEN					
019908 002	ZOLPIDEM TARTRATE; AMBIEN					
020789 001	ZONISAMIDE; ZONEGRAN				NCE	MAR 27, 2005
020789 002	ZONISAMIDE; ZONEGRAN				NCE	MAR 27, 2005
020789 003	ZONISAMIDE; ZONEGRAN				NCE	MAR 27, 2005

## Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c)(3)(5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
  - DS = Drug Substance claim
  - DP = Drug Product claim
  - U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- \*PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with \*PED as was done prior to August 18, 2003. Patents with \*PED added after August 18, 2003 will not contain any information relative to the patent itself other than the \*PED extension. Information related specifically to the patent will be conveyed on the original patent only.